

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF FLORIDA
MIAMI DIVISION

CASE NO. 10-CV-22236-ASG/GOODMAN

HOWARD ADELMAN AND JUDITH SCLAWY
as Co-Personal Representatives of the
ESTATE OF MICHAEL SCLAWY-ADELMAN,

Plaintiffs,

v.

BOY SCOUTS OF AMERICA;
THE SOUTH FLORIDA COUNCIL INC.,
BOY SCOUTS OF AMERICA; PLANTATION
UNITED METHODIST CHURCH; HOWARD
K. CROMPTON, Individually, and
ANDREW L. SCHMIDT, Individually,

Defendants.

_____ /

AFFIDAVIT OF STEVEN EDWARD LIPSHULTZ, MD, FAAP, FAHA

STATE OF FLORIDA)
)
COUNTY OF MIAMI-DADE)

BEFORE ME, the undersigned authority, on this date, personally appeared **STEVEN EDWARD LIPSHULTZ, M.D.**, who after being first duly sworn, under oath, certifies that the statements set forth in this Affidavit are true to the best of his information and belief and upon personal knowledge and hereby states:

1. My name is Steven Edward Lipshultz, M.D. and I am a resident of the State of Florida. I am over 18 years of age, and I am competent to testify in matters contained in this affidavit.

2. I am Chairman of the Department of Pediatrics at the University of Miami Miller School of Medicine. A copy of my curriculum vitae, which sets forth my background, training and experience is attached hereto as Exhibit "1."

3. I have been retained as an expert witness in the above case by the family of Michael Sclawy-Adelman.

4. I have reviewed the following materials in connection with this matter:

- NMS Laboratory toxicology records
- 2005 Jamboree Materials
- National Park Service Report into Michael's death
- Michael's records from Pediatric Associates
- The Collier County Medical Examiner's file
- The CDC Report for the 2005 Boy Scout Jamboree
- The Heat Index Flag System utilized in the 2010 Jamboree
- The U.S. Marine Heat Index Flag System
- Los Angeles Times article regarding recent Boy Scout deaths.
- Michael's Death Certificate
- Relevant Troop 111 Emails
- Deposition of Andrew Schmidt (Scoutmaster)
- Deposition of Howard Crompton (Scoutmaster)
- Deposition of Kristopher Leon (Fellow Scout)
- Deposition of Dr. Manfred Borges (Medical Examiner)
- Deposition of Dr. William Hearn (Director of Toxicology)
- Deposition of Dr. Ronald Bullard (Pediatrician)
- Medical Literature
- Collier County Sheriff's Department records

5. Even without an autopsy, the evidence, testimony and other information that is available in this matter is more than sufficient to enable a properly qualified medical doctor to reach a medically valid and considered opinion regarding the cause of Michael Adelman's death beyond the degree of reasonable medical probability.

6. Based upon my review and analysis of the materials identified in paragraph 2 above, it is my considered medical opinion that Michael Adelman died as a result of heat stroke within reasonable medical certainty.

7. Even without an autopsy, based upon the evidence, testimony and information set forth above in paragraph 2, there is more than sufficient evidence for a properly qualified medical doctor to weigh the medical possibility and to exclude other potential causes of death, such as pre-existing cardiac abnormalities and brain lesions, within reasonable medical certainty.

FURTHER AFFIANT SAYETH NAUGHT.




STEVEN EDWARD LIPSHULTZ


DATED this 12 day of October, 2011.

BEFORE ME, the undersigned authority, personally appeared, **STEVEN EDWARD LIPSHULTZ**, who is (personally known to me) (or has produced a _____, numbered _____, as identification, which was issued on _____, has an expiration date of _____) and who, being first by me duly sworn, acknowledge that he has read his affidavit and the affidavit is true and correct to the best of his knowledge and belief, and he executed the same in my presence, this 12 day of October, 2011, in Miami, Florida.

SWORN to and SUBSCRIBED before me this 12 day of October, 2011.


NOTARY PUBLIC

My Commission Expires: 9/21/2012



CURRICULUM VITAE

NAME: Steven Edward Lipshultz, MD, FAAP, FAHA
OFFICE ADDRESS: Department of Pediatrics (D820), University of Miami Leonard M. Miller School of Medicine, P.O. Box 016820, Miami, FL 33101
Express mail address: Department of Pediatrics, University of Miami Leonard M. Miller School of Medicine, Medical Campus-MCCD-D820, 1601 NW 12th Avenue, 9th Floor, Miami, FL 33136
OFFICE TELEPHONE: 305 243-3993
OFFICE FAX: 305 243-3990
E-MAIL: slipshultz@med.miami.edu
HOME ADDRESS: 10800 Southwest 68th Avenue
Pinecrest, Florida 33156
DATE OF BIRTH: March 25, 1954
PLACE OF BIRTH: Englewood, New Jersey

EDUCATION:

1976 Bachelor of Arts cum laude – Biology, University of Pennsylvania, Philadelphia, PA
1976 Developmental Biology Program, Marine Biological Laboratory, Woods Hole, MA
1980 Master of Arts - Developmental, Molecular and Cellular Biology, University of Pennsylvania, Philadelphia, PA
1981 Doctor of Medicine, Dartmouth Medical School, Hanover, NH

POSTDOCTORAL TRAINING:

Residency and Fellowship:

1981-1984 Resident in Pediatrics (PL-1 - PL-3), Rainbow Babies and Children's Hosp, Cleveland, OH (Department of Pediatrics, Case Western Reserve University School of Medicine)
1984-1986 Fellow in Clinical Cardiology, Children's Hospital, Boston, MA
1986-1988 Research Fellow - American Heart Association-Bugher Foundation Center for Molecular Biology in the Cardiovascular System (Bugher I Fellow), Children's Hospital, Boston, MA

LICENSURE AND CERTIFICATION:

1982 Ohio Permanent Medical License (# 47138-inactive)
1982-current United States Department of Justice Drug Enforcement Administration Controlled Substances Registration Certificate (Registration # BL0606585 – Expires 3/31/11, DEA Schedules: 2, 2N, 3, 3N, 4, 5)
1985 Massachusetts Medical License (Registration # 54827-inactive)
1986 Massachusetts Controlled Substances License (Registration # ML0343121)
1986-current Diplomate, American Board of Pediatrics, Lifetime Certification in General Pediatrics (Permanent certificate # 33914)
1996-2010 New York Medical License (# 205294, 4880862-inactive)
2003-current Florida Medical License (Lic # ME 89321, Control # 117743, Expiration Date 01/31/2012)
2005-current University of Miami HIPAA (Health Insurance Portability & Accountability Act of 1996) Program Certification. Completed the HIPAA Privacy and Security Awareness CBL and Confidentiality and Acceptable Computer Use Agreements Certification on July 2, 2009.
2005 University of Miami Collaborative IRB Training Initiative Program (CITI Program)

- 2007, 2009 American Heart Association Basic Life Support for Health Care Professionals Recertification
- 2009 Certificate of Completion, National Institutes of Health Information Security Awareness FY09 Refresher (<http://irtsectraining.nih.gov/FYR/certificate.aspx>)
- 2011 CITI Certified and Compliant with IACUC – Completed the Program in Occupational Health for Animal Research Personnel and the Program in Occupational Health and Safety When Working With Laboratory Animals.

ACADEMIC APPOINTMENTS:

- 1986-1991 Instructor in Pediatrics, Harvard Medical School, Boston, MA
- 1990-1995 Assistant Clinical Professor of Pediatrics
Boston University School of Medicine, Boston, MA
- 1992~2000 Assistant Professor of Pediatrics
Harvard Medical School, Boston, MA
- 1995-2006 Associate Research Professor of Pediatrics
Boston University School of Medicine, Boston, MA
- 1996-2003 Professor of Pediatrics (Researcher-Clinician-Teacher Track with Unlimited Tenure)
University of Rochester School of Medicine and Dentistry, Rochester, NY
- 1998-2003 Professor of Oncology
University of Rochester School of Medicine and Dentistry, Rochester, NY
- 2003-2004 Adjunct Professor of Pediatrics
University of Rochester School of Medicine and Dentistry, Rochester, NY
- 2003-current Professor of Pediatrics (Unlimited Tenure)
University of Miami Leonard M. Miller School of Medicine, Miami, FL
- 2003-current Professor of Epidemiology and Public Health
University of Miami Leonard M. Miller School of Medicine, Miami, FL
- 2003-current Professor of Medicine (Oncology)
University of Miami Leonard M. Miller School of Medicine, Miami, FL
- 2006-current Associate Executive Dean for Child Health
University of Miami Leonard M. Miller School of Medicine, Miami, FL
- 2006-current George E. Batchelor Chair in Pediatrics. The contract to establish this endowed chair for the Chairman of the Department of Pediatrics at the University of Miami Miller School of Medicine was signed by the Batchelor Foundation and the University of Miami in 4/06. The chair was fully endowed in 12/09.
- 2006-current Director, University of Miami Child Health Institutes
- 2009-current Graduate Faculty Appointment. Tied to degree programs to work on dissertations. Department of Epidemiology and Public Health. University of Miami Miller School of Medicine and University of Miami Office of Graduate Studies.
- 2010-current Batchelor Family Pediatric Cardiology Endowed Chair. University of Miami
- 2010-current Graduate Faculty Appointment. Graduate Student Mentor. Tied to degree programs to work on dissertations. Department of Molecular and Cellular Pharmacology. University of Miami Miller School of Medicine and University of Miami Office of Graduate Studies.

HOSPITAL APPOINTMENTS:

- 1987-1991 Assistant in Cardiology, Children's Hospital, Boston, MA
- 1991~2000 Associate in Cardiology, Children's Hospital, Boston, MA

1988~2000 Visiting Assistant Physician, Boston City Hospital, Boston, MA
 1996-2004 Attending Pediatrician, University of Rochester Medical Center, Rochester, NY
 1998-2001 Consultant Privileges in Pediatrics, Highland Hospital, Rochester, NY
 2001-2004 Courtesy Privileges in Pediatrics, Highland Hospital, Rochester, NY
 2004-current Attending Physician (Current Membership Category: Active Academic-Pediatric Cardiology. Original Appointment Date: 01/15/04. Admitting Status: Attending with admitting priority one – most recent renewal is for the period 4/21/11-4/20/13) University of Miami-Jackson Memorial Medical Center, Public Health Trust Medical Staff, Miami, FL, JHS System ID Number 04887
 2003-current Chief-of-Staff, Holtz Children’s Hospital of the University of Miami-Jackson Memorial Medical Center, Miami, FL
 2005-current Teaching Attending Physician, Pediatric Team B, Holtz Children’s Hospital of the University of Miami-Jackson Memorial Medical Center, Miami, FL
 2007-current Attending Physician, Jackson North Medical Center, Miami, FL
 2009-current Provider, South Florida Community Care Network

OTHER PROFESSIONAL POSITIONS:

1986-1991 Clinical Investigator Award
 National Institutes of Health - National Heart, Lung and Blood Institute
 1988-1996 Director, Division of Pediatric Cardiology, Boston City Hospital
 1989-current Member, National Steering Committee and Site Principal Investigator, Pediatric Cardiac and Pulmonary Complications of HIV Infection Study. National Institutes of Health. National Heart, Lung and Blood Institute
 1990-current Principal Investigator, National Pediatric Cardiomyopathy Registry
 1993-current Chairman, Several Cardiology Writing Committees, Pediatric Cardiac and Pulmonary Complications of HIV Infection Study. National Institutes of Health. National Heart, Lung and Blood Institute
 1994-2001 Chairman, National Cancer Institute Pediatric Oncology Group Protocol 9480
 1994-2002 Principal Investigator, FDA IND #53,073 for Pediatric Cardiomyopathy Usage of Enalapril
 1994-2003 Chairman, National Cancer Institute Pediatric Oncology Group Cardiology Network
 1994-2003 Core Member, Cancer Control Committee, National Cancer Institute Children’s Oncology Group
 1991-2006 Core Member, Adolescent and Young Adult (AYA) Committee and member of the AYA Strategy Group, National Cancer Institute Children’s Oncology Group
 1995-current Cardiology Investigator, Children’s Oncology Group Protocols 9404, 9425, 9426, 9754, AOST0121, National Cancer Institute
 1995-current Study Chair/Principal Investigator, Pediatric Cardiomyopathy Registry. NHLBI study. ClinicalTrials.gov Identifier: NCT00005391. Study ID Numbers: 4297.
 1995-current Study Investigator, Combination Chemotherapy and Radiation Therapy in Treating Children With Acute Lymphoblastic Leukemia. NCI study. ClinicalTrials.gov Identifier: NCT00004034. Study ID #: CDR0000066202, DFCI-95001, DFCI-FDR001197, NCI-G99-1651. (<http://clinicaltrials.gov/ct2/show/NCT00004034>).
 1995-current Study Investigator, Treatment of Childhood Acute Lymphoblastic Leukemia. NCI study. ClinicalTrials.gov Identifier: NCT00165087. Study ID Number: 95-001.
 1996-current Chairman, Steering Committee, National Heart, Lung, and Blood Institute Pediatric Cardiomyopathy Registry (PCMR)

1996-2003 Chief, Division of Pediatric Cardiology, University of Rochester Medical Center/Golisano Children's Hospital at Strong

1996-2003 Member, Strong Children's Research Center

1997 Member, NCI Intergroup Osteosarcoma Working Group

1997-2007 Study Chair/Principal Investigator, Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer (A Randomized double-blinded phase III Study: Afterload reduction therapy for late anthracycline cardiotoxicity: A Pediatric Oncology Group cancer control study). NCI study. ClinicalTrials.gov Identifier: NCT00003070. Study ID Numbers: CDR0000065745, POG-9480, NCI-P97-0086. (<http://clinicaltrials.gov/ct2/show/NCT00003070>).

1998-2003 Member, University of Rochester James P. Wilmot Cancer Center

1998-2003 Director, Translational Research, Golisano Children's Hospital at Strong

1998- 2003 Director, Children's Heart Center at Strong

1999-2003 Director, Pediatric Heart Transplantation Program, University of Rochester

2000-2007 Co-Program Director, National Heart Lung and Blood Institute Research Training Program in Preventive Cardiology. University of Rochester

2001-current Key Investigator, Food and Drug Administration, Center for Drug Evaluation and Research, Animal Study Protocols OTR-01-132 and 3: Discovery and Evaluation of Interspecies Biomarkers of Acute and Chronic Drug-induced Myocardial Injury

2001 Member, International Consensus Conference on Clinical and Biological Insights in HIV-associated Cardiovascular Disease in the HAART Era. Policlinico S. Matteo, Pavia, Italy

2002-current Chairman, Medical Advisory Board, Children's Cardiomyopathy Foundation, Inc.

2002 Member, Board of Directors, Children's Cardiomyopathy Foundation

2002 Member, Centers for Disease Control and Prevention and American Heart Association Consensus Committee on Inflammatory Markers in Heart Disease

2002-2003 Associate Chair of Pediatrics for Strategic Planning, University of Rochester Medical Center and Golisano Children's Hospital at Strong

2002-2003 Co-director, Pediatric Cardiac Intensive and Intermediate Care Units, University of Rochester Medical Center and Golisano Children's Hospital at Strong

2002-current Study Chair/Principal Investigator, Effects of Highly Active Anti-Retroviral Therapy on Cardiovascular Health in Infants of HIV-Infected Mothers. NHLBI study. ClinicalTrials.gov Identifier: NCT00253682. Study ID Numbers: 1342; RO1 HL72705

2003-current Member, NCI Children's Oncology Group ALTE03N1 "Key Adverse Events after Childhood Cancer" Study Committee (Protocol activated 3/22/04, revised 7/12/07)

2003-current Chairman, Department of Pediatrics, University of Miami Leonard M. Miller School of Medicine

2003-current Chief-of-Staff, Holtz Children's Hospital of the University of Miami-Jackson Memorial Medical Center

2003-current Director, Batchelor Children's Research Institute – A designated integrated center created in 1999 at the University of Miami for the advancement of child health research. The institute contains both clinical and laboratory research projects.

2003-current Associate Director, Mailman Center for Child Development

2003-current Member, Board of Directors, Greater Miami Pediatric Society

2003-current Member, Florida Association of Children's Hospitals, Inc. (FACH), a Council of the Florida Hospital Association

2003-current	Member, Executive Committee and Chairs Committee, Florida Pediatric Society and the Florida Chapter of the American Academy of Pediatrics
2003-current	Member, Executive Committee, University of Miami Medical Group
2004-current	Member, Jackson Memorial Foundation Golden Angel Society Physician Group
2004-current	Member, Community Board of Directors, American Heart Association, Miami-Dade Division of the Florida/Puerto Rico Affiliate
2004-2009	Member, Scientific Steering Committee, Sylvester Comprehensive Cancer Center, Miami, FL
2005-2007	Member, Executive Committee, Association of Medical School Pediatric Department Chairs, Inc. (AMSPDC)
2004-current	Study Chair/Principal Investigator, Long-Term Effects of Highly Active Anti-Retroviral Therapy on HIV-Infected Children. (HAART Associated Cardiotoxicity in HIV-Infected Children Study). NHLBI study. ClinicalTrials.gov Identifier: NCT00260806. Study ID Numbers: 1318; RO1 HL78522
2005-current	Chairman, Board of Oversight, NHLBI and CCF North American Pediatric Cardiomyopathy Biologic Specimen Repository
2006-current	Co-chair, Combined NHLBI Pediatric Cardiomyopathy Registry and Pediatric Heart Transplant Study Group Writing Committee #2 "Transplant as End-Stage Therapy"
2006-current	Protocol Team Member, Pediatric HIV/AIDS Cohort Study (PHACS): Surveillance Monitoring for ART Toxicities Study in HIV-uninfected Children Born to HIV-infected Women (SMARTT Study). Protocol PH 100. NICHD, NHLBI, NIAID, NIDA, NIMH, NIDCD
2006-current	Protocol Team Member, Pediatric HIV/AIDS Cohort Study (PHACS): Adolescent Master Protocol (AMP Study). Protocol PH 200 (Version 2.0 January 4, 2008). NICHD, NHLBI, NIAID, NIDA, NIMH, NIDCD
2007-2008	Invited Member, Data Safety Monitoring Board, Muscular Dystrophy Association grant for an imaging study and biomarker analysis associated with a treatment arm for cardiomyopathy in Duchenne Muscular Dystrophy (Texas Children's Hospital, Jeffrey Towbin, MD-PI)
2007-2008	Member, Internal Advisory Committee (IAC), Miami Institute for Medical Discovery and Health Disparities (MIMDHD) for proposed NIH Clinical and Translational Science (CTSA, RFA: RM-07-002) award application
2007-2008	Chair, Research Education, Training and Career Development (RETCD) Steering Committee, Miami Institute for Medical Discovery and Health Disparities (MIMDHD) for proposed NIH Clinical and Translational Science Award (CTSA, RFA: RM-07-002) application. This is a 17-member Steering Committee that is the locus for direction and management of the RETCD Division of the MIMDHD
2007-current	Member of 4-person Internal Advisory Committee (IAC) of the University of Miami NIAID Developmental Center for AIDS Research (D-CFAR)
2007-current	Member of Executive Oversight Committee, University of Miami Comprehensive AIDS Program
2007-current	Faculty Member of the NHLBI-sponsored University of Miami "Training Program in Cardiovascular Signaling"
2008-current	Member, DCFAR Executive Committee, University of Miami
2008-current	Mentor, Pediatric Academic Societies Pediatric Research Student Program
2008-current	Member, Association of Medical School Pediatric Department Chairs, Inc. (AMSPDC) Mentor's Leadership Development Program for New Chairs

2009-current	Investigator, US FDA White Oak Animal Program Animal Study Protocol Number: WO-2009-88: Examination of Tyrosine Kinases Inhibitor-Induced Cardiotoxicity: A Comparison with Doxorubicin. Dr. Eugene Herman, PI
2009-current	Registered Member, National Cancer Institute-sponsored Phase III Cancer Treatment Trials as a registered member of the Cancer Trials Support Unit (CTSU). NCI Cooperative Group Treatment Affiliation: COG. NCI Cancer Therapy Evaluation Program (CTEP) ID number: I-24775 (Westat). On March 29, 2011 this NCI Investigator ID number 24775 was renewed
2009-current	Member, HESI Cardiac Safety Technical Committee. Member of two working groups: 1. Predictive Cardiovascular Strategies Team – to review current technologies and identify opportunities for integrating new and more predictive paradigms. 2. Functional Cardiovascular Strategies Team – to review current technologies and indentify gaps in our current functional cardiovascular assessment paradigms
2009-current	Member, BioPsychoSocial Oncology (BPSO) Core. University of Miami Sylvester Comprehensive Cancer Center. (www.sylvester.org/BPSO)
2009-current	Member, Research Resource Strategies Council. Miami CTSA application
2009-current	Member, Scientific Advisory Board, Miami CTSA application
2009-current	Member – Advisory Panel for the Research Education, Training and Career Development Component, Miami
2009-2010	Chair, Miami Scholars Program, Miami CTSA application
2009-current	Director, University of Miami Pediatric Integrative Medicine Program – A federally funded center to improve child health and development through an evidence-based, pediatric-centered integrative medicine program
2010-current	Member, COG Late Effects of Dexrazoxane Randomized Trial Protocol. NIH

AWARDS AND HONORS:

1977	Full Member, Sigma Xi (National Honorary Research Society, University of Pennsylvania chapter)
1977	Scholarship, Gordon Research Conference on Developmental Biology, Tilton, NH
1977	First Federal Academic Achievement Scholarship
1983	Rainbow Pediatric Pharmacology Research Award
1984	W. B. Saunders Resident Research Award
1987	American Medical Association Physician Recognition Award
1987-1988	American College of Cardiology - Bristol Laboratories Affiliate Cardiology Fellow Research Travel Award
1988-1990	American Medical Association Physician Recognition Award
1989-2002	American Medical Association Physician Recognition Award
1991	NIH Site Visit Member, Baylor College of Medicine, National Heart, Lung and Blood Institute, NIH
1991	NIH Site Visit Member, Mount Sinai School of Medicine, National Heart, Lung and Blood Institute, NIH
1991	NIH Site Visit Member, College of Physicians and Surgeons, Columbia University, National Heart, Lung and Blood Institute, NIH
1992	NIH Site Visit Chairman, UCLA School of Medicine, National Heart, Lung and Blood Institute, NIH
1992	Distinguished Alumnus Award, Tenafly High School, Tenafly, New Jersey

1992 Annual Resident Teaching Award, Boston City Hospital and Boston University School of Medicine

1992 Saul Usher Visiting Professor, McGill University School of Medicine (Montreal Children's Hospital)

1993 Visiting Professor, Albert Einstein University School of Medicine (Montefiore Medical Center)

1993 Company Leader, American Heart Association Heart Walk, Boston, MA

1994 Visiting Professor of Pediatrics and Cardiology, Baylor College of Medicine (Texas Children's Hospital)

1996 Member, NHLBI Director's Advisory Committee, Pediatric Cardiology Specialized Centers of Research (SCOR) Program

1996 Member, NHLBI Director's Advisory Committee, Intramural Cardiomyopathy Research

1996 Invited Member, NHLBI Workshop, "From Developmental Biology to Molecular Biology

1997 Member, NHLBI Data and Safety Monitoring Board. NIH Interventional Therapeutic Trials for Hypertrophic Cardiomyopathy

1997 Member, NHLBI-NIDA Advisory Committee, Cardiac HIV-Alcohol Research Program

1998 Member, NHLBI-NIDA Advisory Committee, Cardiac HIV-Cocaine Research Program

1998 Member, Pediatric Advisory Board, Merck and Company

1998 Invited Member, NCI Workshop, "Research Issues in Cancer Survivorship"

1998 Consultant, NCI Common Toxicity Criteria International Guidelines

1998 Member, Pharmacia and Upjohn Dexrazoxane Advisory Board

1998-1999 Ad Hoc Voting Member, FDA ODEC Oncology Drug Review Group

1998 Visiting Professor, Department of Pediatrics, Stanford University School of Medicine

1998 Visiting Professor, Emory University School of Medicine

1998 Member, NHLBI-NIDA Study Section on HIV/Cocaine Cardiovascular Disease

1998 Member, Data Safety Monitoring Board, Phase II Randomized, Parallel Group, Multiple Dose Study of Lodenosine (FddA) in Combination with Stavudine and Indinavir in Antiretroviral-Naïve, HIV-Infected Adult Patients. US Bioscience

1998 Member, Bioscience International Roundtable on Carnitine for Cardiomyopathy and Ischemia

1998 Academic Sabbatical (June 1998-November 1998), University of Rochester School of Medicine and Dentistry

1998-current Consultant, FDA Center for Biological Evaluation and Review

1999 Member, Scientific Advisory Board, Liposomal Doxorubicin Development and Trials, The Liposome Company

1999 Abstract Reviewer, 2000 Pediatric Academic Societies' and American Academy of Pediatrics Joint Meeting

2000 Member, NHLBI-NIDDK Special Emphasis Panel Review Committee for RFA HL-00-007: Protease Inhibitor Related Atherosclerosis in HIV Infection

2001 I. Bruce Gordon Visiting Professor of Pediatrics, MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio

- 2000 Member, NCI Leukemia, Lymphoma, and Myeloma Progress Review Group Roundtable Meeting
- 2001 Member, Management of Cardiovascular-Renal Complications Group. American Heart Association Scientific Conference Prevention VI: Diabetes and Cardiovascular Disease
- 2001 Member, Cardioxane (Dexrazoxane) Advisory Board, Chiron Corporation
- 2001 Visiting Professor, Children's Hospital of New York-Presbyterian (Morgan Stanley Children's Hospital), Columbia-Presbyterian Medical Center, New York, NY
- 2002 Visiting Professor, Medical University of South Carolina, Charleston, SC
- 2002 George S. Husson-Maria S. Blackman Visiting Professor, Department of Pediatrics, Upstate Medical University and State University of New York, Health Science Center, Syracuse, NY
- 2002 Member, Heart Committee, National Cancer Institute Late Effects Criteria and Applications Workshop
- 2001-2003 Peer-selected for listing, Best Doctors in America (www.bestdoctors.com). The listing is based on a national survey of doctors, ranking colleagues in their areas of specialization
- 2002 Member, US Centers for Disease Control and Prevention and the American Heart Association Workshop on Inflammatory Markers and Cardiovascular Disease: Application to Clinical and Public Health Practice
- 2002 Member, National Cancer Institute Workshop on "Pediatric Long-Term Follow-up Clinic Programs Consortium." Niagara-on-the-Lake, Canada
- 2002 Visiting Professor of Pediatrics, Academic Medical Center, Emma Children's Hospital, and University of Amsterdam, The Netherlands
- 2002 Member, National Cancer Institute Workshop on "Research Initiatives in Long-Term Cancer Survivorship." Bethesda, MD
- 2003 Donald S. Fyler Visiting Professor, Department of Pediatrics, Harvard Medical School and Children's Hospital, Boston, MA
- 2003 Visiting Professor of Pediatrics, Arkansas Children's Hospital, Little Rock, AK
- 2003 Consultant, Pediatric Oncology Cochrane Systematic International Review Group, Amsterdam, Netherlands
- 2003 Member, Children's Oncology Group Late Effect of Childhood Cancer Guidelines Committee and Writing Group
- 2003 Medical Consultant, Hepatitis C Therapy Cardiotoxicity. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
- 2003 Member, National Cancer Institute Workshop on "Pediatric Long-Term Follow-up Clinic Programs Consortium." Bethesda, MD
- 2003 Health Care Achievement Awards 2003 Physician Finalist. Rochester Business Journal, Rochester, NY
- 2003 Invited Participant, Centers for Disease Control and Prevention (CDC) and Lance Armstrong Foundation Workshop on "Partnership to Advance Cancer Survivorship and Public Health." Austin, TX
- 2003 Invited Participant, NHLBI Workshop on "HIV Cardiovascular Dis." Bethesda, MD.
- 2003 Moderator, Annual Associated Medical Schools of New York Medical Student Research Competition, Rochester, NY
- 2003 Chairman, NHLBI Study Section on Animal Models of HIV Heart, Lung, and Blood Diseases, Bethesda, MD

2003 Member, Study Section Reviewing Grants Submitted to the Lance Armstrong Foundation, Austin, TX

2003-2005 Peer-selected for listing, Best Doctors in America. The listing is based on a national survey of doctors, ranking colleagues in their areas of specialization

2004 Member, BILN 2061 Cardiotoxicity Clinical Expert Group Meeting, Boehringer Ingelheim Pharmaceutical Corporation, Miami, FL

2004 The R. Rodney Howell, MD Invited Lectureship, Master's of Pediatrics Program, University of Miami School of Medicine, Miami, FL

2004 Visiting Professor of Pediatrics, Academic Medical Center, Emma Children's Hospital, and University of Amsterdam, The Netherlands

2004 Member, NIH Special Emphasis Panel ZHL1 CSR-S(M1) Specialized Center of Research (SSCOR) in Cardiac Dysfunction and Disease Review (RFA HL-03-009), Bethesda, MD

2004 Member, 44th Annual Conference on Cardiovascular Disease Epidemiology and Prevention of the American Heart Association Abstract Review Program

2004 Invited Member, American Heart Association Study Section, Orlando, FL

2004 Visiting Professor, MD Anderson Cancer Center and The University of Texas School of Medicine, Houston, TX

2004 Francisco A. Hernandez Annual Lectureship – University of Florida Division of Pediatric Cardiology and the Southern Pediatric Cardiology Association. Orlando, FL

2004 Invited Member, Lance Armstrong Foundation Study Section, Austin, TX

2004-current Chair, Micah Batchelor Child Health Research Grant Program, Miami, FL

2004 Member, Miami Children's Hospital Small Grant Committee

2004 Invited Member, Children's Cardiomyopathy Foundation Grant Review Program, New Orleans, LA

2004 Visiting Professor, Miami Children's Hospital, Miami, FL

2004 Marquis Who's Who in America 2006

2005 Member, 45th Annual Conference on Cardiovascular Disease Epidemiology and Prevention of the American Heart Association Abstract Review Program

2004-2005 Peer-selected for listing, Best Doctors in America (www.bestdoctors.com). The listing is based on a national survey of doctors, ranking colleagues in their areas of specialization

2004 Figura Del Dia. (Figure of the Day). El Nuevo Herald Newspaper. July 8, 2004

2005 Florida's Best Doctors, Florida Monthly Magazine

2005 Health Care Heavy Hitters Award, South Florida Business Journal

2005 Top NIH Grantee Recognition for being above the 95th percentile of the distribution of extramural NIH grants over the last 25 years. Columbia University

2005 Consultant, Amgen, Inc.

2005 Co-chair, Green Family Health Initiative Research Award Grant Review Committee.

2005 Member, Miami Children's Hospital Small Grant Program Committee

2005 Member, NIH NHLBI Special Emphasis Panel Working Group on "Cardiomyopathies of Rare Diseases." NHLBI Division of Heart and Vascular Diseases and the NIH Office of Rare Diseases, Bethesda, MD

2005 Member, NIH National Center for Research Resources Initial Review Group – Site Visit by Clinical Research Review Committee [RIRG-G (02)], Children's Hospital

of Philadelphia 2 RR M01-000240-42 General Clinical Research Center Grant, Philadelphia, PA

2005 Invited Member, Lance Armstrong Foundation Survivorship I Grant Review Study Section, Austin, TX

2005 Recipient. Madelon Ravlin Award for Cancer Research. The Women's Cancer Association. Miami, FL

2005 Member, NIH Clinical and Integrative Cardiovascular Sciences (CICS-CSR) Initial Review Group, Bethesda, MD

2005 Member, American Heart Association Study Section, Orlando, FL

2005 Member, Pediatric Advisory Committee, National Clinical Trial of Nesiritide in Children with Congestive Heart Failure, Scios Corporation

2005 Member, 46th Annual Conference on Cardiovascular Disease Epidemiology and Prevention in association with the Council of Nutrition, Physical Activity, and Metabolism of the American Heart Association Abstract Grading Program

2005 Invited Member, Children's Cardiomyopathy Foundation Grants Review Committee

2005-2007 Peer-selected for listing, Best Doctors in America. The listing is based on a national survey of doctors, ranking colleagues in their areas of specialization

2005 Selected by the American Heart Association as the Award Recipient for the Scientific Sessions 2005 Poster Competition in Clinical Science

2005 Member, Scientific Oversight Com, NIH Pediatr HIV/AIDS Cohort Study (PHACS)

2005-current Member, PHACS Cardiology Group

2005-2006 Chairperson, National Institute of Allergy and Infectious Diseases Special Emphasis Panel [ZAI1 DDS-A (M1)] "Units for HIV/AIDS Clinical Trials Network (SEP 10). (RFA AI-05-002) Review Group

2005 Member, US Congressional and US Department of State Official Delegation Led by United States Undersecretary of State Dr. Paula Dobriansky and United States Congressman Lincoln Diaz-Balart to examining the Children of Chernobyl and State of Pediatric Health Care, Kiev, Ukraine

2006 Member, Stanley Glaser Award Review Committee, University of Miami

2006 Chairman and Member, Data and Safety Monitoring Board. Protocol BPSC030: A Phase I/II Study of the Safety and Pharmacokinetics of Opebacan (Recombinant Bacteriocidal/Permeability Increasing Protein - rBPI₂₁) in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). XOMA (US) LLC Corporation, Berkeley, California

2006 Invited Member, Data and Safety Monitoring Board. Phase III Celecoxib Pediatric (ages 10-17 years old) FAP Multicenter Trial (PI – Patrick Lynch, MD, MD Anderson Cancer Center, Houston, TX)

2006 Member, American Heart Association Southern and Ohio Study Group 1A (Peer Review Committee 1: Cardiovascular Development, Lung, Respiration and Resuscitation Surgery, Radiology and Imaging). Orlando, FL

2006 Recipient, First Ross Visiting Professorship in Pediatrics, Department of Pediatrics, New York University School of Medicine, New York, NY

2006 Recipient, Genevieve Abrahm Award for "tireless dedication to improve outcomes in children's health through clinical care, education, advocacy and medical research." University of Miami Miller School of Medicine Project: New Born

2006 Selected for inclusion. Florida's Best Doctors 2006. Florida Monthly Magazine, June 2006 (Volume 26, Number 6)

- 2006 Member, Mechanistic Markers of Toxicity (MMT) Working Group within the Genomics Technical Committee, International Life Sciences Institute Health and Environmental Sciences Institute (HESI). A working group for biomarker development to bridge non-clinical/preclinical studies to the clinic
- 2006 Member, National Heart, Lung, and Blood Institute Special Emphasis Panel (ZHL1 CSR-O [01]) for the Mentored Clinical Scientist Development Award (K08) and Independent Scientist Award for Postdoctoral Individuals and New Independent Researchers (K02) Applications
- 2006-current Member, Children of Chernobyl Relief and Development Fund Medical Advisory Committee, Whippany, New Jersey
- 2006 US Congressional Commendation. On April 25, 2006 US Congressman Lincoln Diaz-Balart said in the Congressional Record "I am also truly optimistic regarding the relationship that has been forged between physicians at the University of Miami's School of Medicine and physicians from Ukraine, and I commend Dr. Steven Lipshultz for spearheading this worthy endeavor." Congressional Record-Extension of Remarks, April 25, 2006, Page E584 (http://bulk.resource.org/gpo.gov/record/2006/2006_E00584.pdf)
- 2006 Recipient, Medal of Smila. An award of "courage, fortitude and the victory of good over evil" by the Town of Smila, Cherkasy Oblast, Ukraine
- 2006 Member, CONQUER (Cardiology Oncology InterNational Quest to Educate and Research Heart Failure) Committee. M.D. Anderson Cancer Center
- 2006-2008 Member, HIV and Cardiovascular Disease Advisory Working Group. Co-chair of Writing Group 4 on Vascular Disease, Cardiovascular Diseases in HIV (CDV/HIV) Advisory Working Group (AWG). An initiative of the American Heart Association and American Academy of HIV Medicine
- 2006 Member and Second Chair (when the chair was in conflict). Lance Armstrong Foundation Grants Program Survivorship 1 Study Section
- 2007 Elected to Full Membership, Association of American Physicians
- 2006 Founding Member, Leukemia and Lymphoma Society Late Effects Research National Advisory Committee
- 2006 Nominator, 2007 Lasker Med Res Awards, Albert & Mary Lasker Foundation
- 2006 Visiting Professor of Pediatric Cardiology. Great Ormond Street Hospital for Children NHS Trust. London, England
- 2006 Keynote Address Speaker. Royal Society of Medicine Symposium entitled "Cancer Therapy Improvement by Toxicity Reduction & Cardioprotection." London
- 2006-2007 Selected for listing as one of "America's Top Cardiologists" in the "Guide to America's Top Cardiologists." Consumers' Research Council of America
- 2007 Member, American Heart Association Southern and Ohio Valley Study Group 1A (Peer Review Committee 1A: Cardiovascular Development, Lung, Respiration and Resuscitation Surgery, Radiology and Imaging). Tampa, FL
- 2007 Member, Stanley J. Glaser Foundation Biomedical Research Support Grant Program Review Committee, University of Miami Miller School of Medicine
- 2007 Chair, NIH Pediatric AIDS Cohort Study (PHACS) Cardiology Working Group.
- 2007 Mail Reviewer – Temporary Member, NIH NeuroAIDS and Other End-Organ Diseases (NAED) Initial Review Group. Center for Scientific Review (7/17/2007)
- 2007-2009 Peer-selected for listing, Best Doctors in America (www.bestdoctors.com)

2007 Selected for listing as one of "America's Top Cardiologists" in the "Guide to America's Top Cardiologists. Consumers' Research Council of America

2007 Reviewer, Doris Duke Clinical Scientist Development Award. University of Miami

2007 Nominator, 2008 Lasker Medical Res Awards, Albert & Mary Lasker Foundation

2007-2008 Advisor, 2008 Cardiometabolic Health Congress, Boston, MA

2007-current Invited Member, Pediatric Cardiology Roundtable of Leaders of the American Academy of Pediatrics, Association of Medical School Pediatric Chairs, American College of Cardiology, and Pediatrics for Current Procedural Terminology (CPT) Coding Reform

2007-2008 Invited Member, Committee to Create the Barilla Children's Hospital, Parma, Italy

2007-2008 Member, International Board Committee, Casa Ricordi 1808-2008

2008 Abstract Reviewer and Panel Speaker. First Annual University of Miami, Miller School of Medicine Cardiovascular Research Symposium

2008-current Invited Charter Member, Camp Boggy Creek's Medical Advisory Committee. This is Florida's Hole in the Wall Camp for children with serious illnesses (cancer, heart disease, epilepsy, hemophilia, renal failure, sickle cell, rheumatic diseases, asthma, diabetes, spina bifida, and those on home ventilators) founded in 1996 by Paul Newman and General Norman Schwartzkopf

2008-current Member, representing University of Miami Miller School of Medicine, to the American Medical Association Section on Medical Schools (AMA-SMS)

2008 Invited Visiting Professor of Pediatrics. Robert Wood Johnson Medical School. University of Medicine and Dentistry of New Jersey. New Brunswick, New Jersey

2008 Visiting Professor of Pediatrics. University of South Florida School of Medicine, Tampa General Hospital, Tampa Florida

2008 Visiting Professor of Pediatrics. All Children's Hospital, Saint Petersburg, Florida

2008 Recipient, Archie & Bill Clot Memorial Award. The Woman's Cancer Association of the University of Miami. 50th Annual Installation & Grant Distribution Luncheon. Miami, FL

2008 Invited Member, Hypertrophic Cardiomyopathy Advisory Board. PGxHealth Division, Clinical Data, Inc. "Elite expertise in cardiovascular genetic disease testing and development of therapeutic products."

2008 NCI notified us that Dr. Lipshultz' program in Pediatric Oncology Translational Research "has been identified as an exemplar of NCI-Funded translational research."

2008 Invited Member of the Predictive Biomarkers for Cardiac Toxicity Group. Institute of Medicine of the National Academies's Forum on Drug Discovery, Development, and Translation Conference on Safety Biomarkers entitled: "Assessing and Accelerating Development of Biomarkers for Drug Safety." Washington, DC. Focus: what are the most important questions that need to be asked to better understand and predict drug induced nephrotoxicity, hepatotoxicity, and cardiac toxicity?

2008-2009 Selected for listing as one of "America's Top Cardiologists" in the "Guide to America's Top Cardiologists." Consumers' Research Council of America

2008-current Invited Member, Child Health Planning and Advocacy Committee of Florida Children's Medical Services Regional Medical Directors and the District X of the American Academy of Pediatrics

2008 and 2010 Invited to become a Member of The Royal Society of Medicine, London, England

2008-current Chair, Writing Group 6 on Cardiomyopathy. World Health Organization Global

2008-2009 Burden of Disease Project (CDC)
 Scientific and Preclinical and Clinical Data Reviewer, GlaxoSmithKline External Expert in Drug-Induced Cardiotoxicity and the Role of Biomarkers in Predicting this Toxicity

2009 The Robert Freedom Lecturer and Visiting Professor. The Hospital for Sick Children, University of Toronto, Toronto, ON, CA (October 2009)

2008-current Active Member, Full Steering Committee, National Children's Study, Eunice Kennedy Schriver National Institute of Child Health and Human Development

2008-2011 Invited Voting Member – Executive Steering Committee, National Children's Study, Eunice Kennedy Schriver NICHD

2008-current Co-chair. National Children Study Southeast US Principal Investigator's Group. Eunice Kennedy Schriver NICHD

2009-2010 Selected as "Top Doctor", Castle Connolly America's Top Doctors® Guide. ID: 91CC001943). Based on physician nominations and subsequent research, 7,000 doctors are selected to help guide consumers to America's top doctors

2009 Nominated for Membership, Institute of Medicine, National Academy of Science

2009 Elected Fellow of the American Heart Association (FAHA)

2009 Chair, Clinical Science Abstract Review Committee, Second Annual University of Miami, Miller School of Medicine Cardiovascular Research Symposium

2009 Member, Advisory Committee, American Heart Association Initiative to Decrease Cardiovascular Risk and Increase Quality of Care for Patients Living with HIV

2009 Chairman, Medical Advisory Board, for the joint American Heart Association (AHA)/Children's Cardiomyopathy Foundation (CCF) Pediatric Cardiomyopathy Research Award. The CCF provides partial funding to support an AHA Beginning Grant-in-Aid or Grant-in-Aid that is specific to pediatric cardiomyopathy

2009 Nominated, American Heart Association Miami-Dade Heart and Stroke Ball Second Cor Vitae (Heart of Life) Award. "An individual who, through their professional accomplishments and commitments, significantly influenced advancement in the field of cardiovascular diseases."

2009 Member of the Selection Committee. Samuel Rosenthal Prize for Excellence in Academic Pediatrics. Samuel Rosenthal Foundation of Cleveland, the Leighton A. Rosenthal Family Foundation, and the Milton A. and Charlotte R. Kramer Charitable Foundation. Initiated in 1995 as a global award

2009 Invited Pediatric Oncology Group of Ontario Visiting Professor. McMaster University, Hamilton, Ontario, Canada

2009 NIH Study Section Member. Internet Assisted Review (IAR). Center for Scientific Review Special Emphasis Panel/Scientific Review Group 2009/10 ZRG1 MDCN-A (58) R – RFA OD-09-003 mdcn NIH Challenge Grants panel meeting. 7/20/2009

2009 NHLBI Study Section Member. Internet Assisted Review (IAR) with an Asynchronous Electronic Discussion (AED) review mechanism. NIH Support for Conferences and Scientific Meetings (PA-08-149) (Parent R13/U13) Special Emphasis Panel (SEP)/Scientific Review Group 2009/10 ZHL1 CSR-W (01) 1 meeting. Agenda Seq Num – 216026. August 13-14, 2009

2009 NCI notified us that Dr. Lipshultz' program in Pediatric Oncology Translational Research (RO1CA127642) was selected to "have your research represented at this important 2009 National Cancer Institute (NCI) Translational Science Meeting

(TSM2) to Accelerate Translational Science initiative to advance the most promising translational research projects.”

2009 Lead representative for clinical sciences on the organizing committee. 2010 University of Miami Cardiovascular Research Symposium

2009 Founding Member and Healthcare and Research Partner, HeartScreen Florida. To provide preventive heart screening services to athletes, students, and health-conscious consumers to help prevent sudden unexpected death and detect heart disease to ensure a long, healthy life

2009-2010 Selected for listing as one of “America’s Top Cardiologists” in the “Guide to America’s Top Cardiologists, 2009 Edition.” Consumers’ Res Counc of America

2009-2010 Peer-selected for listing, Best Doctors in America 2009-2010 database

2009 Dr. Lipshultz’ work in cardiovascular disease in HIV/AIDS was highlighted by the NHLBI in a peer-reviewed article in the Journal of the American College of Cardiology on September 22, 2009 entitled “News from the NHLBI: Cardiovascular Disease in Adult and Pediatric HIV/AIDS.”

2009-2010 Invited Member, Scientific Advisory Boards of the International Academy of Cardiology and of the 15th World Congress on Heart Disease, Invited Member, Awards Committee to select recipients of the 5-2010 Awards, Vancouver, BC, Canada, July 24-27, 2010

2010 Invited Scientist and Seminar Speaker. Cardiovascular Safety Pharmacology Division, Roche Corporation, Nutley, NJ. Focus on cardiovascular safety pharmacology, troponin and oncology

2010 Member, Review Panel, National Heart, Lung, and Blood Institute Special Emphasis Panel for an R24 (Resources) Grant Application entitled “BioRepository for Investigation of Neonatal Diseases of the Lung (BRINDL).” July 2010

2010 Selected as one of “America’s Top Pediatricians” in the “Guide to America’s Top Pediatricians, 2010 Edition.” Consumers’ Research Council of America

2010 Mission Speaker, Leukemia & Lymphoma Society Triathlon Miami Event Inspiration Dinner, Miami

2010-current Member, Leadership Council, Leukemia & Lymphoma Society, Southern Florida Chapter

2010-current Consultant-Pediatric EMA Pixantrone Investigative Plan. Cell Therapeutics, Inc.

2010-current Consultant-Cardiovascular Safety Pharmacology, Roche Corporation

2010-current Member, Steering Committee, NHLBI Training Grant in Cardiovascular Signaling-yrs 34-40. Director-James Potter, PhD, Molecular and Cellular Pharmacology, UM

2010 Visiting Professor, University of Connecticut Health Sciences Ctr, Hartford, CT

2010 Selected as one of “America’s Top Cardiologists” in the “Guide to America’s Top Cardiologists, 2010 Edition.” Consumers’ Research Council of America

2010-2011 Member, Scientific Advisory Boards of the International Academy of Cardiology and of the 16th World Congress on Heart Disease. Annual Scientific Sessions 2011, Vancouver, BC, Canada, July 23-26, 2011

2010 Visiting Professor. Japanese Society of Pediatric Cardiology and Cardiac Surgery and the Tokyo Women’s Medical University. Tokyo, Japan

2010-current Member, Publications Committee, Eunice Kennedy Shriver National Institute of Child Health and Human Development National Children’s Study-focused on official primary publications writing teams

- 2010 Our research was selected by the National Cancer Institute as the lead featured article on NCI-supported research in their journal, NCI Bulletin, for 9/15-30/10.
- 2010 Notified by the National Cancer Institute that our work was featured in October 2010 as an “excellent exemplar” of NCI-supported comparative effectiveness research.
- 2010 Visiting Professor. City of Hope Comprehensive Cancer Center. Duarte, CA
- 2010-current Chair, Cardiology Task Force, NICHD PHACS Study
- 2010 Chair, Children’s Cardiomyopathy Foundation Scientific Review Committee
- 2011-2012 Peer-selected for listing, Best Doctors in America 2011-2012 database
- 2011 Second Annual Mary Allen Engle Visiting Lecturer and Visiting Professor. Department of Pediatrics, Joan and Sanford I. Weill Cornell University Medical College and New York-Presbyterian Phyllis and David Komansky Center for Children’s Health
- 2011 Albert Dorfman, MD, PhD, Distinguished Lecturer and Visiting Professor. Department of Pediatrics, University of Chicago and Comer Children’s Hospital
- 2011 Grant Reviewer, NHLBI R13 (Conference Grant) Review Panel. (3/29-30/11)
- 2011 Grant Reviewer, NHLBI Special Emphasis Review Panel-RFA-HL-10-024 “Ancillary Studies in Clinical Trials (RO1). Research grant applications to conduct time-sensitive ancillary studies related to heart, lung, and blood diseases and sleep disorders in conjunction with ongoing clinical trials and other large clinical studies supported by NIH or non-NIH entities. (<http://grants.nih.gov/grants/guide/RFA-HL-RFA-HL-10-024.html>) (4/15/2011)
- 2011-2012 Selected for Inclusion, Who’s Who in America – 2012 (66th Edition). Marquis Who’s Who
- 2011-2012 Selected for Inclusion, Who’s Who in the World – 2012. Marquis Who’s Who
- 2011 Selected as one of “America’s Top Cardiologists” in the “Guide to America’s Top Cardiologists, 2011 Edition.” Consumers’ Research Council of America
- 2011 Member-Advisory Board. PROCARDIO European Commission Study
- 2011 Visiting Professor of Pediatrics, Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York
- 2011 Grant Reviewer, NHLBI Special Emphasis Review Panel-RFA-HL-10-024 “Ancillary Studies in Clinical Trials (RO1). Research grant applications to conduct time-sensitive ancillary studies related to heart, lung, and blood diseases and sleep disorders in conjunction with ongoing clinical trials and other large clinical studies supported by NIH or non-NIH entities. (<http://grants.nih.gov/grants/guide/RFA-HL-RFA-HL-10-024.html>) (8/15/2011)
- 2011 Member of the Selection Committee. Samuel Rosenthal Prize for Excellence in Academic Pediatrics. Samuel Rosenthal Foundation of Cleveland, the Leighton A. Rosenthal Family Foundation, and the Milton A. and Charlotte R. Kramer Charitable Foundation. Initiated in 1995 as a global award

GRANTS AND CONTRACTS: Prior to the current grants and contracts listed below Dr. Lipshultz had 132 completed awards, on 80 of which he was the principal investigator. He has been continuously funded since 1985.

CURRENT GRANT AND CONTRACT SUPPORT:

Total Annual Direct Costs of Grants/Contracts Directed To Dr. Lipshultz = ~\$27,424,150

<u>ACTIVE (Grant #, name, and PI)</u>	<u>Current Annual Direct/Total Cost</u>
<u>A. Federal Funding</u>	<u>~\$11,637,078</u>
1. 5 RO1 HL 078522-02 Steven E. Lipshultz HAART Associated Cardiotoxicity in HIV-Infected Children	8/01/04-7/31/11 \$276,691/\$399,329
2. 2 RO1 HL 053392-11 Steven E. Lipshultz Pediatric Cardiomyopathy Registry (scored 2%ile)	6/15/05-5/31/12 \$749,997/\$928,373
3. NIH (NCI) 1RO1CA127642: Genetic Mechanisms of Anthracycline Cardiotoxicity in Pediatric Cancer Survivors (SE Lipshultz, PI – scored at 130/3.3%)	9/28/07-8/31/11 \$281,881/\$349,997
4. P01 CA 068484 Steven E. Lipshultz (subcontract) Maximizing the Therapeutic Index of Childhood ALL (Scored 129 – first in study section)	5/01/06-4/30/12 \$55,766/\$84,485
5. 1U01HD052104 Steven E. Lipshultz (Investigator) Pediatric HIV/AIDS Cohort Study Coordinating Center (Scored 142 - 1 st in study section) (TL Miller, subcontract PI)	9/01/05-8/31/15-renewed for 5-years \$25,662/\$38,878
6. 1 U01 HD052102-01, CDFA No. 93-865 Clinical Site for the Pediatric HIV/AIDS Cohort Study (PHACS) Adolescent Master Protocol (AMP) Study (Scott GB PI, Seage GR-PI PHACS Data and Operations Center, Lipshultz SE Investigator)	8/1/06-7/31/15-renewed for 5 years 5% \$75,000/
7. 1 U01 HD052102-01, CDFA No. 93-865 Clinical Site for the Pediatric HIV/AIDS Cohort Study (PHACS) Surveillance Monitoring For Antiretroviral Treatment Toxicities (SMARTT) Study (Scott GB PI, Seage GR-PI PHACS Data and Operations Center, Lipshultz SE Investigator)	8/1/06-7/31/15-renewed for 5 years 5% \$75,000/
8. 1RO1HL079233 (William Shearer, MD, PI; (SE Lipshultz, Investigator on UM subcontract): Sleep Studies in HIV+ Older Children/Adolescents.	6/1/06-5/31/12 \$152,542 (total costs/1 year)
9. 1R01HL087000-01A1: Pediatric Cardiomyopathy Specimen Repository. (JA Towbin, PI, subcontract PI - SE Lipshultz, Scored 150/7.1% - 7/07 funded in full).	12/1/06-11/30/11 \$22,135/\$33,790 Total – \$415,050/\$558,107
10. NIH (NHLBI)2T32HL007188-31A1: Training Program in Cardiovascular Signaling (JD Potter, PI; SE Lipshultz, Mentor, submitted 6/06, Scored 154 on 11/28/06, notified 3/7/07 that is funded for 5 years)	4/1/07-3/30/12 511,082/538,452 zero to Dr. Lipshultz
11. NIH (NIAID: 5P30AI073961) DCFAR Grant (S Pahwa, MD – PI) University of Miami Developmental Center for AIDS Research (SE Lipshultz – Member, Internal Advisory Committee; submitted 9/06; scored at 176,	4/1/07-3/31/12 none to Dr. Lipshultz

- funded-started on 6/1/07)
12. NIH SCOR-NIDA-P50: Emmalee S. Bandstra-PI 9/1/07-8/31/12
Specialized Center of Interdisciplinary Research 750,000/1,151,823
on Sex and Gender Factors Affecting Women's Health: "Sex and Gender Influences on Addiction and Health: A Developmental Perspective". None to Dr. Lipshultz
(S. Lipshultz – Chair, Internal Advisory Committee).
Reviewed on 3/22/07 and received a priority score of 159 (NIDA stated that this score was the best type 1 application). Funded 9/07
 13. NIH F41- HL094100-01: J Alvarez-PI 9/30/08-9/29/11
Pediatric Cardiomyopathy 100,000?
(Dr. Lipshultz is the mentor on this NRSA) None to Dr. Lipshultz
First submission score was 160.
 14. NIH (NHLBI – 1RO1HL095127-01) 9/26/08-9/25/11
RFA-HL-08-003 (TL Miller MD, PI Total/3 years = \$1,147,500
Atherosclerotic Risk and Response to \$17,800/year
Exercise in HIV+ Children (SE Lipshultz, Investigator) to Dr. Lipshultz (10%)
Funded on first submission.
 15. NIH (EASTRFPNIH-NICHD-NCS-08-21E): 9/26/08-9/25/13
University of Miami Florida National Children's Study ~\$54,600,000 (total 5-year costs with
(NCS) Center. Four separate Locations: 1. Miami-Dade options)
County NCS Center, 2. Baker County NCS Location,
3. Hillsborough County NCS Location, and
4. Orange County NCS Location. (Lipshultz SE, PI)
(submitted 5/2/08 – Positive initial review-6/08 – Best and Final
Offer – 8/08 – funded on first submission)
Contract#: HHSN27500800002C, NICHD Ref. # N01-HD-8-0002
 16. NIH 1 K01 DA026993-01 (Messiah S, PI) 07/01/09-06/30/14
Growth and Cardiometabolic Risk Among In Utero Drug 133,233/143,892
Exposed Children. (Lipshultz, SE, co-mentor) zero to Dr. Lipshultz
4/09 Priority Score on First Submission – 151
Funded on first submission
(Mentored Research Scientist Development Award)
 17. HRSA Pediatric Integrative Medicine Research Center 7/1/09-6/31/14
(Lipshultz SE, PI) (Submitted 3/14/08, \$235,620
3/11/09-funded for \$238,000
initially and then \$235,620)
HRSA-9827 (3/18/09 7:31 e-mail). In an e-mail
from 10/8/09 this was referred to as Grant number:
C76HF15614. This is a HCOF grant
(Health Care and Other Faculties) through
the Health Resources and Services Administration (HRSA).
 18. NICHD 1RO1HD060325-01 (Miller TL – PI) 9/30/09-8/31/11
(Lipshultz S – investigator) Dietary intakes and patterns, 367,518/521,396
biomarkers and maternal and infant outcomes in HIV.
UM proposal M0901783. Funded with one submission.

19. DHHS Pediatric Integrative Medicine Research Center (Lipshultz SE, PI) (Submitted 3/14/09) 7/1/10-6/30/15
 On Feb 26, 2010 we were informed that we received this as a "Health Care and Other Facilities" (HCOF) grant for \$742,500 with a current identification number of 10679. \$1,441,260/\$952,000
 Funded at \$750,000
20. NIDA CTN (Drug Abuse Clinical Trials Network) Florida Node (J Szapocznik, PI; SE Lipshultz, investigator, and other roles - submitted 10/09. Score received 2/25/10 and is a 2.0 [outstanding] – funded). 9/1/10-8/31/15
 10% salary to Dr. Lipshultz
 1,190,702/5,768,540
 10,206/12,033-sl
21. NICHD National Children's Study (Lipshultz SE, PI) Contract#: HHSN27500800002C, 9/26/08-9/25/13
 NICHD Ref. # N01-HD-8-0002 Call for Letters of Intent to Participate in Evaluation of Additional Recruitment Strategies for the National Children's Study (Restricted to Current Centers under National Children's Study Contract with Vanguard, Wave 1, or Wave 2 Status) University of Miami submitted on 01/20/2010:
 1. Hillsborough County Provider-Based Recruitment
 2. Hillsborough County Enhanced Household Recruitment
 3. Orange County Enhanced Household Recruitment
 4. Baker County Enhanced Household Recruitment – on 2/1/10 we were officially notified that this was selected by the NICHD for funding. Funding has been secured and activation is occurring. ~\$54,600,000 (total 5-year costs)
22. NIH-RO1NR012885 (Miller TL, Gerschenson M, co-PIs, Lipshultz SE-investigator). Mitochondrial determinants of pediatric HIV metabolic disorders. Favorably reviewed at 9/10 NINR Council. NOGA awarded 9/30/10. 9/30/10-9/29/15
 ~\$450,000 annual direct costs
23. HHS/Agency for Healthcare Research and Quality (AHRQ-10-10005) RFP entitled "Accelerating Change and Transformation in Organizations and Networks (ACTION II)." (PI-Battelle-Dr. Manninen, Site PI-S Lipshultz). Submitted 3/10/10. Confirmation of completion received 3/31/10. Review 7/10. Advances in innovations in health care delivery and quality will occur through research initiatives through this 11-center women and child healthcare partnership network. This stresses access to a large a diverse clinical population, state-of-the-art research expertise and infrastructure, and contract research experience. 8/1/10-7/31/15

On July 2, 2010 we (Battelle Memorial Institute as prime) heard that our technical and business proposals was found in the competitive range and questions were due July 15, 2010.

In August 2010 we were notified that this was selected for funding. This was funded as a five-year task order contract model known as ID/IQ and could be funded for up to five years and up to \$100 million as the ACTION II program by the US Department of Health and Human Services Agency for Healthcare Research and Quality (AHRQ).

At a time when the US government is moving forward on child care reform the Agency for Healthcare Research and Quality (AHRQ) had wanted to create a platform to evaluate

different child health reform proposals. We at UMMSOM-Child Health worked with Battelle Memorial Institute to respond to the AHRQ RFP requesting proposals for this purpose. We heard in writing this month that we have been selected to receive this network although it will not be publically announced for another few weeks. This should be THE platform the government uses to test child health care reform. Budgets will be specific to projects.

The Battelle proposal with us has clearly laid out its vision and requirements for “Accelerating Change and Transformation in Organizations and Networks,” known as the ACTION II partnerships. In response, Battelle has created the Battelle Women and Children’s Healthcare Partnership, which we are part of and involves a select group of partners with whom we have all successfully collaborated on major projects. The Battelle Partnership is committed to practice-based implementation research as critical to effective healthcare for all Americans through evidence-based assessments of an innovation’s effectiveness in specific care settings. Our partnership includes Arkansas Children’s Hospital Research Institute (ACHRI), Baylor College of Medicine (BCM), and Texas Children’s Hospital (TCH), Duke University School of Medicine, Emory University School of Medicine and Children’s Healthcare of Atlanta, Nationwide Children’s Hospital, Saint Louis University (SLU) School of Medicine, The Ohio State University (OSU), Arizona Respiratory Center at the University of Arizona College of Medicine, University of Miami Miller School of Medicine, University of Texas Southwestern Medical Center (UTSMC), and Washington University School of Medicine (WUSM).

UM Child Health based our partnership on critical elements required to meet AHRQ’s goal for ACTION II of accelerating all aspects of evidence-based innovation in healthcare delivery and organization to measurably improve healthcare in the United States. Access to this funded platform provides the proving ground for testing, implementing, and taking to scale innovations in healthcare and includes some of the largest, most diverse, and most impactful healthcare delivery systems in the United States, with a focus on women and children.

Together, this partnership serves and provides access to healthcare delivery to more than 3 million patients, including more than 1.7 million children, and significant numbers of rural, low-income, and minority patients. Services include acute inpatient, ambulatory, specialty clinics, and primary care—the range of practice that determines healthcare for children and women. This network is also geographically and culturally diverse, providing the opportunity for understanding regional and cultural differences in the effectiveness of innovations.

Studies that provide unbiased and quality data to draw inferences about effectiveness require established research expertise in study design, standardized protocols, information technology, human subjects, and other specialized research skills. Our new network has institutions committed to practice-based research and infrastructure that includes state-of-the-art medical and information technology, as well as hospitals, clinics, practice-based research networks, and institutional review boards. Our network is committed to effective implementation, testing, and dissemination of innovations and will has a culture that values innovation, as well as routine adoption and familiarity with the latest developments in healthcare.

- | | |
|--|---------------------------------------|
| 24. NICHD, National Center for Toxicological Research/FDA,
others. (Lipshultz S, PI). NCTR Master Project # and
also Initial Project ID: E0728711,
Funding IAG/CRAD with NICHD, Addendum-\$611,720.40.
Cardiac Biomarkers to Assess Methylphenidate:
Evaluation of growth and cardiovascular function in
30 male rhesus monkeys (<i>Macaca mulatta</i>) chronically
exposed to methylphenidate hydrochloride (MPH). | 7/1/11-6/30/12
\$181,632/\$269,453 |
|--|---------------------------------------|

Objective: To determine whether cardiac biomarker levels are associated with echocardiographic measures of abnormal cardiac structure and function. Hypothesis: Biomarkers of acute myocardial injury, inflammation, hemodynamic instability, end-organ effects, or cardiac remodeling will be associated with abnormal echocardiographic measures of cardiac structure or function. To determine whether panels of cardiac biomarker levels will more accurately predict echocardiographic and clinical status than do individual biomarkers. Panels of cardiac biomarkers can be identified that will more accurately predict echocardiographic or clinical endpoints than can individual biomarkers. Scientifically approved.

Final budget requested and tentatively approved in 9/10.

(Division: SystemsTox, Branch: HepatoTox). NCTR Director: William Slikker, Jr; NCTR PI: William F. Salminen;

NCTR Co-invest: Daniel R. Doerge. UM IACUC Approval received 6/9/11 (#11-156) and NCTR Approval received (Protocol E-2800).

<u>B. Other Funding (Pharmaceutical, Foundation, Other)</u>	<u>\$15,687,072</u>
1. Lance Armstrong Foundation (Steven Lipshultz, MD) Prevention of mtDNA Mutations with Dexrazoxane in Pediatric Cancer Survivors	1/01/05-12/31/11-extended \$224,969/\$247,466
2. Women's Cancer Association (Steven Lipshultz, MD) Determination of the Effectiveness of Dexrazoxane as a Cardioprotectant in Long Term Survivors of Leukemia Treated with Anthracycline	6/01/05-5/31/12 \$50,000/
3. GlaxoSmithKline (Steven Lipshultz, MD) Pediatric Cardiomyopathy Registry - Coreg (carvedilol) Study-Protocol #103639	9/01/04-2/28/14 \$1,739,106/\$2,173,883
4. Chiron Corporation Ltd. (Steven Lipshultz, MD) Treatment of Acute Lymphoblastic Leukemia 8/06 Novartis Oncology, Basel acquired Chiron and took over this grant.	7/22/05-6/30/14 \$356,493/\$445,616
5. Pharmacia & Upjohn-A Pfizer Company (Steven Lipshultz, MD) Dexrazoxane Cardioprotection-DFCI Treatment of Acute Lymphoblastic Leukemia UM088071 Pfizer#10150, Tracking#WS282503, Legacy Tracking#2005-0360, External ID#88071	7/01/97-11/30/14 \$720,704/\$900,880
6. Pharmacia & Upjohn-A Pfizer Company (Steven Lipshultz, MD) Dexrazoxane Cardioprotection-COG POG Protocols 9494; 9425; 9426; 9754 A Reference Lab for Echos and Biomarkers for Zinecard UM088072 Pfizer#10158-A, Tracking#WS277116, Legacy Tracking#2005-0364	7/01/97-11/30/14 \$809,586/\$1,011,983
7. Roche Diagnostics Corporation (Steven Lipshultz) Biomarker Sub-Study of Treatment of Childhood Acute Lymphoblastic Leukemia (ALL), DFCI 95-001	8/01/05-7/31/14 \$58,548/\$58,548

8. Roche Diagnostics Corporation (Steven Lipshultz) Biomarker Sub-Study of Cardiac Risk Factors in Pediatric Cancer Survivors	8/01/05-7/31/14 \$3,408/\$3,408
9. Roche Diagnostics Corporation (Steven Lipshultz) Biomarker Sub-Study of Characterization of Serum Biochemical Markers of Myocardial Injury in Neonates.	8/01/05-7/31/14 \$3,468/\$3,468
10. Roche Diagnostics Corporation (Steven Lipshultz) Biomarker Sub-Study of Myocardial Damage in Children with Presumed Viral Illness	8/01/05-7/31/14 \$3,228/\$3,228
11. Roche Diagnostics Corporation (Steven Lipshultz) proBNP, hsCRP and Sub-clinical Cardiac Status in Pediatric Chronic Renal Failure	8/01/05-7/31/14 \$3,900/\$3,900
12. Roche Diagnostics Corporation (Steven Lipshultz) Biomarker Sub-Study of Cardiovascular Status of Highly Active Antiretroviral Therapy (HAART) Exposed Infants/Children	8/01/05-7/31/14 \$121,380
13. Roche Diagnostics Corporation (Steven Lipshultz) Biomarker Sub-Study of Protocol for Patients with newly Diagnosed Non-Metastatic Osteosarcoma	2/07/06-6/06/14 \$14,352
14. Roche Diagnostics Corporation (Steven Lipshultz) Biomarker Sub-study of Intergroup Phase II Window Of Herceptin in Osteosarcoma Patients with Tumors that Overexpress HER2	2/07/06-6/06/14 \$3,300
15. Children's Cardiomyopathy Foundation (Steven Lipshultz) Pediatric Cardiomyopathy Registry: Biological Specimen Repository	4/01/05-3/31/14 \$6,000/\$7,500
16. Florida State Department of Health (FSDH CMS COQFO) (Steven Lipshultz) Children's Medical Services: Medical Director Contract	7/01/05-6/30/12 \$10,777/\$11,640
17. Florida State Department of Health (FSDH CMS COQFB) (Steven Lipshultz) In and Out Patient Services Contract	7/01/05-6/30/12 \$824,384/\$890,335
18. Florida State Department of Health (FSDH COQ FO) (Steven Lipshultz, Medical Director) Consolidated Contract: Hematology/Gastroenterology/Endocrinology Adolescent Medicine	7/01/05-6/30/12 \$878,168/\$948,421
19. University of Miami Quasi-Endowment Account Steven Lipshultz, MD Dr. Lipshultz' Pediatric Cardiac Research Quasi-Endowment	8/15/04-current \$554,671 – as of 12/31/06=596,980 + \$19,500 Parker #20 below 1/11
20. Parker Family Foundation - Steven Lipshultz, MD Pediatric Cardiomyopathy Research (includes 12/22/08 grant for \$6,500, 12/09 for \$6,500, 12/09/10 for \$6,500) (Included in #19 above)	1/1/97-12/31/15 \$62,000
21. Perini Quality-of-Life Program Steven Lipshultz MD	1/1/95-12/31/11

Afterload Reduction for Late Doxorubicin Cardiotoxicity (Included in #19 above)	\$75,000
22. Glover-Crask Trust. Steven Lipshultz, MD Pediatric Cardiomyopathy Research (Included in #19 above)	12/99-12/11 \$175,000
23. Children's Cardiomyopathy Foundation. (Steven Lipshultz, MD) Baseline Predictors of Outcome in Children with Cardiomyopathy: PCMR Analyses (Included in #19 above)	2/1/03-1/31/12 \$30,000
24. Muscular Dystrophy Association. Steven Lipshultz, MD. Pediatric Neuromuscular Disease Research Program (Batchelor Foundation) (total \$900,000)	7/1/05-6/30/12 \$900,000 (received MDA check 1403795 for \$100,000 on 2/10/09 as a gift from the Batchelor Foundation to advance pediatric neuromuscular disease research, received Batchelor Foundation check to MDA for \$100,000 on October 2, 2009)
25. Sylvester Comprehensive Cancer Center Grant Steven Lipshultz, MD Pediatric Oncology Cardiac Research Unrestricted	12/01/04-11/30/11 \$10,000
25. Greenberg May Foundation Grant Steven Lipshultz, MD Program in Pediatric Cardiac Rehabilitation for Children with Chronic Illness (Included in #19 above)	4/01/05-3/31/12 \$5,000
26. Fondation LeDucq Grant Steven Lipshultz, MD, collaborator (Robert J. Myerburg, MD, PI) Preventing Sudden Cardiac Death	10/1/05-9/30/10 0 to Dr. Lipshultz \$1,071,026
27. Covance 6194-106/Proposal 79961C-1 Troponin T in Anthracycline Cardiotoxicity	10/1/06-9/30/11 \$1000
28. Children's First Research Fund Unrestricted	\$65,999
29. University of Miami Pediatric Event Fund Unrestricted	\$72
30. Batchelor Women's Cancer Fund Restricted	\$100,000
31. Research Education and Care/ Batchelor Unrestricted	\$4,230
32. ROA – Mailman Center Program Funds Unrestricted	\$3,320
33. Rose and Irving Zimmerman Research Fund Unrestricted	\$54,427
34. Pediatric Mobile Clinic Prog Restricted	\$413,834
35. Micah Batchelor Endowment Interest Restricted	\$300,000
36. Child Action Project	

Restricted	\$7,975
37. Marian Friedman Memorial Fund	
Restricted	\$1,782
38. Step Program – Pediatrics	
Restricted	\$3,275
39. Robert Stempfel Scholarship Fund	
Restricted	\$2,975
40. Gastroenterology Research Fund	
Restricted	\$1,018
41. Kenneth Boyd Bernstein Memorial Fund	
Restricted	\$57,918
42. Pediatric Residents Fund	
Restricted	\$6,279
43. The Children’s Fund	
Restricted	\$5,039
44. Paul Freund Children’s Research Fund	
Restricted	\$415
45. Physical Therapy Fund	
Restricted	\$2,881
46. Pediatric Cardiac Research Quasi Endowment Fund	
Endowment	\$28,758
47. W. Alton Jones Pediatric Endowment Fund	
Endowment	\$52,217
48. Mary McComas Endowment Fund	
Endowment	\$13,932
49. Holladay Endocrinology Fund	
Endowment	\$5,689
50. McKey Cystic Fibrosis Endowment Fund	
Endowment	\$2,546 - 12/31/06=\$635
51. Berenson Chair in Pediatric Cardiology	
Endowment	\$39,065 – 12/31/06=\$43,952
52. Child Development Endowment	
Endowment	\$424,951
53. Al and JL Mailman Endowment	
Endowment	\$465,786
54. Charlotte and Anna Gross	
Endowment	\$146,186
55. Batchelor Family Chair in Cystic Fibrosis	
Endowment	\$155,776 – 12/31/06=\$162,179
56. RH Endowed Chair For Research	
Endowment	\$78,183 – 12/31/06=\$10,212
57. Harold B. Smith Endowment Fund	
Endowment	\$196,016
58. Adolescent Medical and Psychiatric Program Fund	
Endowment	\$459,894
59. Chairman’s Fund	
Unrestricted	\$2,948,743

60. U Allocation Teaching and Research Fund Unrestricted	\$1,241,513
61. South Florida Spinal Cord Injury Center Restricted	\$146
62. University Center of Excellence – Mailman (90DD0565-03) Restricted	\$7,100
63. Public Health Trust – Chec Funds Restricted	\$98,844
64. Bone Marrow Transplant Nurse Agreement Restricted	\$93,518
65. Children’s Cardiomyopathy Foundation PCMR Studies of Serial Echocardiography and Nutritional Status as Predictors of Outcome and The Effect of Ethnicity (Lipshultz, PI)	\$25,000 1/1/07-12/31/11
66. Papanicolaou Corps for Cancer Research Inc. Mark Our Words Program (Jessica Davis)	\$1,200 6/1/06-5/31/12
67. Bankhead Coley Cancer Research Program Bridge Grant (Florida Biomedical Research Program) (S Lipshultz, PI). Genetic Mechanisms of Anthracycline Cardiotoxicity in Pediatric Cancer Survivors. (Submitted 2/07 and scored 1.0 by reviewer - funded).	7/01/07-6/30/09 \$200,000/
68. Sylvester Comprehensive Cancer Center Supplemental RO1 Funding (S Lipshultz, PI). Genetics of Anthracycline Cardiotoxicity.	2/1/08-1/31/12 \$30,000/
69. Women’s Cancer Association (S Lipshultz, PI). Reduction of Doxorubicin (Adriamycin®) Cardiotoxicity in Long-Term Survivors of Childhood Leukemia by Dexrazoxane (Zinecard®): Understanding of Mechanisms and Sub-populations Most Likely to Benefit by Use of Dexrazoxane.	5/10/08-5/9/12 \$50,000/
70. Singulex, Inc. (S Lipshultz, PI). Explore the ability of the Singulex cardiac troponin-I high sensitivity immunoassay to detect drug induced cardiac damage in humans. This is likely to be extended and we have a budget of \$68,323.68 pending in 11/08.	8/5/08-8/4/11 ~\$15,000 in assays
71. 2010 Cardiomyopathy Conference Support. (UM Account #305249) (S Lipshultz, PI). (Funds from the Myocarditis Foundation, the Children’s Cardiomyopathy Foundation, and others)	4/12/10-4/11/12 ~\$50,000
72. Women’s Cancer Association (S. Lipshultz, PI) Why are girls at greater risk of doxorubicin (Adriamycin) heart damage And why do girls benefit more from dexrazoxane (Zinecard) heart protection than boys? (Funded 5/15/10 for \$40,000)	7/1/10-6/30/12 \$50,000
73. Dana-Farber Research Associate Support (S. Lipshultz, PI)	3/1/2010-2/28/2012 \$50,000
74. American Society of Hematology 2010 Trainee Research Award. PI-Scully R. Mentors-Lipshultz SE, Sallan SE.	7/1/10-6/30/12 \$5,000

- | | |
|--|-----------------------------|
| 75. Hyundai "Hope on Wheels" Grant – Pediatric Comprehensive Cancer Survivorship Program (Lipshultz SE, PI) | 9/1/10-8/31/11
\$100,000 |
| 76. American Heart Association Predoctoral Scientist Award (PI, Landy DC, Mentor, Lipshultz SE). Cardiovascular issues in cancer survivors | 7/1/11-6/30/14
\$50,000 |
| 77. Dana Farber- Michael Garil Foundation ALL Grant (Lipshultz SE, PI) | 6/1/11-5/31/12
\$50,000 |

PENDING - Total Annual Costs of Pending Grants Directed To Dr. Lipshultz = \$17,970,261 (estimate)

- | | |
|--|---|
| 1. NIH (CTSI): Miami Clinical and Translational Science Institute 1U54RR031279-01A1, NIH application ID: 8174957 (J Szaposznik, PI; SE Lipshultz, investigator, and other roles - submitted 10/10. 2/23/11-Impact/Priority Score=19 | 7/1/11-6/30/16
-/
10% salary to Dr. Lipshultz |
| 2. NHLBI 1 R01HL109090-01-Cardiac Biomarkers in Pediatric Cardiomyopathy. (Lipshultz SE – PI) Submitted 10/5/10. Assigned to CASE (Cardiovascular and Sleep Epidemiology Study Section-Population Sciences and Epidemiology) Integrated Review Group, Center for Scientific Review 2/11/11-Impact/Priority Score=25, Percentile=22.0-1 st submission. Pending NIH appeal. Also a revised application was submitted 6/28/11. | 7/1/11-6/30/16
\$7,235,569 |
| 3. NHLBI 1 R01HL111459-01-Genotype-Phenotype Associations in Pediatric Cardiomyopathy. (Lipshultz SE – PI), Assigned to CICS (Clinical and Integrative Cardiovascular Science Integrated Review Group on 2/20/11. SO Name: Patricia Atkinson. Submitted 2/4/11. 6/24/11-Impact/Priority Score-21, Percentile-10% Likely to be funded. | 9/1/11-8/31/16
\$11,304,199 |
| 4. NIH T32 Medical Scientist Training Program (MSTP) Grant for the University of Miami (Lemmon SK-PI, Lipshultz SE-Mentor) Submitted 2/2010. | |
| 5. NIH RFA-HD-09-006: Limited competition for the Pediatric HIV/AIDS cohort study (U01). Submitted 10/28/09. Reviewed 3/10. Approved for funding. Active but do not have details. | |
| 6. NHLBI P01 (Gillman M – PI, Lipshultz S – Subcontract PI) Early Origins of Cardiovascular and Respiratory Health and Disease: A Project Viva PPG. Submission was on 5/25/10. S. Lipshultz is the Project 2 Project Leader and this project is entitled: Fetal cardiac biomarkers and altered cardiac structure/function in early adolescence. S. Lipshultz is also part of the Clinical Core Leadership group and the PO1 overall leadership group. Reviewed with project 2 scoring at 28. Resubmitted 5/11 - pending. | 11/1/10-10/31/15
\$1,515,000/yr TDC
10% FTE - SEL |
| 7. NHLBI RO1 (Murry C-PI, Lipshultz S-Subcontract PI) Induced pluripotent stem cells and pediatric cardiomyopathy Submitted 2/10. Scored 39. To be resubmitted-In revision. | 12/1/10-11/30/15
\$239,870-UM subcontract |
| 8. HHS-HRSA (Health Resources and Services Administration) Labor/Health and Human Services/Education FY2011 Appropriations Request #M1001503. Submitted 2/26/10. | 10/1/10-9/30/11
\$2,324,567 |

- Childhood Obesity Prevention Program, a Division of the Pediatric Integrative Medicine Center (PIMC) at the University of Miami. Grant #C76HF15614/ Award#1 C76HF15614-01-00 (Lipshultz S-PI)
9. Mills Charity Foundation (Lipshultz S-PI) 7/1/10-6/30/11
 Pediatric Integrative Medicine Center Equipment Grant \$12,823
 Submitted 2/26/10
10. NICHD National Children's Study (Lipshultz SE, PI) 9/26/08-9/25/13
 Contract#: HHSN27500800002C, NICHD Ref. # N01-HD-8-0002 ~\$54,600,000 (5-year costs)
 Call for Letters of Intent to Participate in Evaluation of Additional Recruitment Strategies for the National Children's Study. We submitted on 3/12/2010 six grant formative research LOI proposals for development and evaluation of study visit measures and assessments that include the University of Miami NCS Center. The National Children's Study. Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH
 In order of priority for submission:
- 10-1. Visit Assessment Nutrition-The evaluate the feasibility of using the ASA 24 for dietary assessment in pregnant women and young children, as compared to the currently used modified Diet History Questionnaire (DHQ), and also to carry out additional validation work on the DHQ. (Primary-Univ Miami, Lipshultz PI, Tracie L. Miller-LOI PI) – On April 6, 2010 we were notified that this proposal was selected to be invited to develop a further second level more specific proposal to conduct this respective formative research project as an ad hoc consortium. Second phase submission completed 5/10. Budget-7/9/10. Funded.
- 10-2. Visit Assessment Health Literacy (Primary-Univ Miami, Lipshultz PI, Sanders-LOI PI). Not funded.
- 10-3. Data Collection New Technology (Primary-Univ Miami, Lipshultz PI, USF-LOI PI). Not funded.
- 10-4. An Autism Spectrum Disorders Case-Confirmed Approach LOI-8 (Primary-Johns Hopkins. L. Goldman, Univ Miami-NCS PI-Lipshultz, Lead Affiliated Autism Researcher-Messinger D). On April 6, 2010 we were notified that this proposal was selected to be invited to develop a further second level more specific proposal to conduct this respective formative research project as an ad hoc consortium. Second phase submission completed 5/10. Budget-7/9/10. Funded.
- 10-5. Field Testing of Environmental Exposure Assessment Methods to Inform Validation Sampling Design Approaches for the National Children's Study. (Primary-Texas Children's, Kozinetz-PI, and Battelle-Strauss W. Univ Miami-Lipshultz, Freeman). Not funded.
- 10-6. Complete Household Sampling to Enhance Recruitment and Retention in the National Children's Study. (Univ Calif Irvine-Swanson-PI, Univ Miami –Lipshultz). Not funded.
- 10-7. Measuring Child Health Disparities: Health Literacy, Discrimination and Health Services (LOI-13) (Johns Hopkins-PI, Univ Miami-Lipshultz, Saunders, L), Notified budget due at NICHD-7/9/10. Funded @ \$650,000 over 18-months to UM.
11. NICHD National Children's Study (Lipshultz SE, PI) 9/26/08-9/25/13
 Contract#: HHSN27500800002C, NICHD Ref. # N01-HD-8-0002 ~\$54,600,000 (5-year costs)
 Call for Letters of Intent (LOI) to Participate in the third in a planned series of announcements for letters of interest to augment Vanguard Study activities with efforts that will accelerate development and deployment of the Main Study, We submitted six grant formative research LOIs

on 07/02/2010 that include the University of Miami NCS Center. The National Children's Study. Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH

The NICHD National Children's Study (NCS) Florida Center is one of 37 NCS study centers and we have all the four NCS Florida counties as potential sites. Our UM Center is one of the most recent NCS centers that the NICHD has activated nationwide and were selected for a \$43 million contract (~\$54.6 million with options) over 5-years of funding.

It appears that 100% of the applications we submitted on the latest round were scored in the funded range through the NICHD contract scientific review process. We anticipate that 100% of these ROI-like grants will be funded by the end of September 2010. If that is the case, this will represent \$7,012,607 in total costs including \$5,778,699 in direct costs and \$3,233,908 in indirect costs over the next year! At a recent NCS Steering Committee NICHD program staff congratulated us for their high regard for the scientific excellence at UM. In looking over the attached list for Round 3 Letters of Intent, only one of the other 37 NCS Centers or 22 CTSA sites around the US had more funded research proposals than UM. All our applications made it into the fundable range by NICHD scientific review and look good to be activated this month.

So what are these awards all about? As you may know the NCS is a 25-year study that will enroll 100,000 children and follow them until they reach 21 years of age to specifically look at epigenetic associations associated with childhood health and disease, as well as in young adulthood. The NICHD identified this year NCS recruitment as a priority and organized a strategy to generate enough events and an adequate cohort size to inform future NCS studies. The NICHD has focused on feasibility, acceptability and cost for the NCS. They subsequently turned their attention to the quality and consistency of the data being collected and are systematically identifying formative research questions to guide the future NCS efforts. One of the overarching logistical and scientific goals is to have consistency of quality and interoperability of data so that subsequent analyses can have the opportunity to make the important associations to address the mandate of the National Children's Study.

The NICHD has used a system of requesting volunteers among the existing contractors to indicate their interest because they believe in general that people will self-identify with regard to expertise and willingness to perform a task. The NICHD has also encouraged input, innovation and even imagination in addressing the tasks to tap into the richness and expertise of the funded NCS Study Centers. For collaboration there are few restrictions and NICHD took some steps such as sharing NCS collaborative opportunities with the approximately 22 Principal Investigators of CTSA sites that are also NCS sites to have the best minds and hands available to support the NCS goals. In addition the NICHD expressly allowed collaborations and subcontracts with justification for the same reasons. So it was a very open field for submitted proposals for research studies.

The NICHD also allowed Study Centers to propose formative research projects on an ad hoc basis so we are sure that important scientific questions and opportunities are identified and addressed.

The formative research and the Vanguard Study are currently the NICHD's mission related to the NCS - to design the best scientifically valid and cost effective NCS possible. With that in mind when the NICHD issued Calls for Letters of Intent to Participate in Evaluation of Additional Recruitment Strategies for the National Children's Study we at UM submitted multiple scientific

proposals to conduct formative research for development and evaluation of study visit measures and assessments that would include the University of Miami NCS Center. The hope is that these selected proposals will accelerate development and deployment of the main NCS Study.

The 12 proposals that UM submitted, have been reviewed by NICHD and felt to scientifically be fundable are noted below:

- 11-1. Enhanced Household Recruitment Model: Baker County, Florida – This proposal is examining enhancement of the household recruitment strategy with selective provider-based activities and expansion of the goals of community engagement to include enumeration, screening, and enrollment in addition to awareness and education is the most appropriate strategy for Baker County and will be successful. [Primary-Univ Miami, Lipshultz PI, Mark Hudak-LOI PI] – Start Date: 8/1/10. End Date: 4/30/11. Direct: \$2,497,934, Indirect: \$79,034, Total: \$2,576,968. Funded.
- 11-2. Implementation and Feasibility of Using the NCI Automated Self-Administered 24-hour Dietary Recall in a USDA-sponsored Preschool Population Study. Visit Assessment Nutrition-Improving Dietary Assessment in Pregnant Women and Children in the National Children's Study. To evaluate the feasibility of using the ASA 24 for dietary assessment in pregnant women and young children, as compared to the currently used modified Diet History Questionnaire (DHQ), and also to carry out additional validation work on the DHQ. (Primary-Univ Miami, Lipshultz PI, Tracie L. Miller-LOI PI (S. Messiah, R. Natale, D Ludwig, K. Hendricks-Dartmouth) – Start Date: 10/1/10. End Date: 9/30/11. Direct: \$106,538, Indirect: \$56,465, Total \$163,003.
- 11-3. Development and Validation of An Autism Spectrum Disorders Case-Confirmed Approach LOI-8 (Primary-Johns Hopkins. L. Goldman, Univ Miami-NCS PI-Lipshultz, Lead Affiliated Autism Researcher- Messinger D, other sites-CHOP, Mt Sinai, UC Davis, UCI, UCLA, UNC, U Pittsburgh, U Washington, Vanderbilt). Start Date: 10/1/10. End Date: 9/30/11. Direct: \$52,513, Indirect: \$26,257, Total: \$78,770.
- 11-4. Measuring Child Health Disparities: Health Literacy, Discrimination and Health Services. Measuring race, ethnicity, language needs and health literacy. (LOI-13) (Johns Hopkins-Tina Cheng, MD-PI, Univ Miami-Lipshultz, LOI PI-Lee Saunders, MD, other sites-UCLA, Univ Hawaii, UCI). Start Date: 10/1/10. End Date: 9/30/11. Direct: \$410,614, Indirect: \$217,625, Total: \$628,239.
- 11-5. RT-01, RT-03, & RT-04: Freshwater Microbial Community PCR Arrays: A Platform for Near Real-time and Comprehensive Water Quality Assessment of Chemical Compounds and Metals (Primary-Univ Miami, Lipshultz PI, Ludwig-LOI PI-UM, UNC, UF, FL-DOH). Start Date: 10/1/10. End Date: 9/30/11. Direct: \$305,789, Indirect: \$50,791, Total: \$356,580.
- 11-6. RT-01: Dedicated laboratory framework for Real Time Analytics in the NCS (Primary-Univ Miami, Lipshultz PI, Phil Chen (HIHG)-LOI PI-Pathology and Hussman Institute for Human Genomics). Start Date: 10/1/10. End Date: 9/30/11. Direct: \$594,362, Indirect: \$293,282, Total: \$887,664.
- 11-7. RT-02: Quality Assessment of NCS Samples for Genetic Analyses (Primary-Univ Miami,

Lipshultz PI, Jacob L. McCauley-LOI PI). Start Date: 10/1/10. End Date: 9/30/11. Direct: \$324,011, Indirect: \$129,326, Total: \$453,337.

11-8. RT-05: Feasibility Studies of Molecular Markers to Identify Pharmacogenomic Profiles and Ancestry Goals: Real time molecular analysis of pharmacogenomic and ancestral markers in consenting adults. (Primary-Univ Miami, Lipshultz PI, Jeff Vance – LOI PI). Start Date: 10/1/10. End Date: 9/30/11. Direct: \$339,081, Indirect: \$179,713, Total: \$518,794.

11-9. PHYS-01: Tools for Screening Pulmonary Function in the NCS. Lung Function in Children 1-8 yrs of age. (Primary- Univ Miami, Lipshultz PI, Andrew Colin, MD – LOI PI, other UM faculty-A. Quizon, MD, E. Forno, MD. St. Christopher's Hospital for Children – Dovey PI). Start Date: 10/1/10. End Date: 9/30/11. Direct: \$322,932, Indirect: \$107,772, Total: \$430,704.

11-10. BIO-02 & RT-01: Cost-Effective Monitoring of Environmental Chemicals in Breast Milk. (Primary-Univ Miami, Lipshultz PI, Battelle – Nancy Wilson, PhD – LOI PI, UM-Emmalee Bandstra, MD and Shahnaz Duara, MD, USF). Start Date: 10/1/10. End Date: 9/30/11. Direct: \$824,925, Indirect: \$93,643, Total: \$918,568.

11-11. LOI-3, Topic RT 01 – Developing Capacity for Genomic Medicine in the National Children's Study. UM, Southern and Central CA, U Washington, Univ Iowa, Mt Sinai, Baylor are part. (Primary-Univ Calif Irvine-Swanson-PI, Univ Miami–Lipshultz) This was scientifically approved and moving forward but UM determined we would not be able to deliver so we have elected not to participate at this time.

11-12. RT-01: (Capacity Building): Topic 02 (Genomics and Epigenomics) and 05 (Ancestry) Submitted by the OCCA/SCCA, PNWNCS, Iowa, Harris County, NY/NJ, and Florida Study Centers (Primary-Univ Calif Irvine-Swanson-PI, Univ Miami–Lipshultz)

12. NIH (David C. Landy, PI, Lipshultz S-Mentor) 1F30HL10696-01 12/1/10-11/30/15
NHLBI Ruth L. Kirshstein National Research Service Awards for Individual Predoctoral MD/PhD Fellows. (Cardiac Risk Factors in Long-term Survivors of Childhood Cancer). Submitted 4/1/10. NIH Appl. ID: 8060075. Impact/priority score in June 23, 2010 at 20. Likely funded. SRG: ZRG1 F16-B. Award Document #: FHL 10691A. Scheduled for 10/10 NHLBI Council. Still active but a revised submission is under review that we submitted 4/11.
13. NCI-RO1 (Travis L-PI, University of Rochester, Lipshultz S-Consultant) 9/30/10-9/29/15
(Platinum toxicity and late effects in treatment of testicular cancer). Submitted 5/25/10. Scored 48. Resubmitted. 8/11-scored 10%ile. Likely funded.
14. NIH RFP-NICHD-CRMC-2010-02 (KAI, PI, Blumer J, PI) 1/1/11-12/31/16
NICHD Pediatric Trials Network (PTN)-University of Miami Pediatric Cardiovascular Clinical Drug Toxicity Center (Lipshultz, S, subcontract PI) Submitted by Rene Kozloff and the KAI PTN Team on 5/28/10. August 2010-additional questions asked by NICHD. Scored second in study section-two points off the best scored proposal.
15. United States Department of Agriculture Coordinated Total funding: \$25 million

- Agriculture Project (CAP) RFA/Grant # A2141
 (Childhood Obesity Prevention) Mikel B.,
 (Mississippi State University), Principal Investigator
 Title: Healthier Opportunities for People through Extension
 (HOPE) 3: Schools as "Hubs" of Community-based,
 Land-grant-led, Obesity Prevention Efforts
 SL Role: Investigator, Miami Data Coordinating Center.
 Submitted 8/2/10. Reverse site visit scheduled in November 2010.
- UM funding: \$2 mill/5 years
 Approximate start date: February 1, 2011
16. P01 CA 068484 Steven E. Lipshultz (investigator, Sallan S-PI) 11/01/11-10/31/16
 Maximizing the Therapeutic Index of Childhood \$55,766/\$84,485
 ALL (Submitted 2/11. Scored 23 [fundable score]- 6/24/11)
17. NHLBI RFP: Data and Clinical Coordinating Center for Pumps 1/15/12-1/14/17
 for Kids, Infants, and Neonates (PumpKIN) Clinical Trials
 Program-Small Business Source Sought Notice Contract Proposal.
 (Rene Kozloff, PhD, KAI-Research, Inc., Rockville, MD, PI;
 Dr Lipshultz-clinical PI). To explore the potential benefit
 of therapy offered by novel pediatric circulatory support devices
 to infants, neonates, and young children (<25 kg) with congenital
 and acquired cardiovascular disease who experience
 cardiopulmonary failure and circulatory collapse at ~20 clinical centers.
 Submitted 3/14/11. In 8/11 was asked further questions to respond to. Pending.
18. NHLBI Competing Renewal: Pediatric Hydroxyurea 1/1/2012-12/31/2017
 Phase III Clinical Trial (Baby HUG) Follow-up II Study
 (Bruce Thompson, PhD, Clinical Trials & Surveys Corp
 (C-TASC)-PI, Lipshultz S-Subcontract PI). Submitted 2/5/11.
 On 9/1/11 heard that the NHLBI has proposed extending follow up
 of BABY HUG through 12/16 (BHFU II) and echocardiograms
 have been included in the study. We have been asked to be
 participate as a central reviewer of the echocardiograms.
19. NIH (NHLBI) 2T32HL007188-36: Training Program 4/1/12-3/30/17
 in Cardiovascular Signaling (D Szczesna-Cordary, PI;
 SE Lipshultz, Steering Committee Member and Mentor. 511,082/538,452
 Submitted 2/5/11-scored 59%ile, to be resubmitted 9/11. zero to Dr. Lipshultz
20. NIH (NHLBI): Stage 2 – Cardiovascular Translational Research 4/1/12-3/31/17
 Implementation Program [CTRIP] to accelerate translation of Total project=
 promising new therapeutic interventions by execution of \$1.5M/yr DC
 well-designed clinical trials to demonstrate safety and efficacy
 derived from fundamental research discoveries for the treatment
 and prevention of CV, lung and blood disease: Phase II Randomized,
 Placebo-controlled, Double-Blind Study of Disease Modification in
 Preclinical HCM. Clinical Network of HCM Centers [HCMNet].
 (Ho C [Harvard-BWH], PI; Dr. Lipshultz' role: Member of
 Trial Advisory Board, HCMNet Clinical Site Principal
 Investigator) (submission 4/4/11)
21. NIH (NICHD) U54 (Blumer J [Univ of Toledo], PI; 9/1/11-8/31/16
 Lipshultz SE, Clinical Site PI) NICHD RFA-HD-10-026: \$500K/yr DC overall
 Specialized centers in research in pediatric developmental

pharmacology program (RPDP). Fund research centers which will provide an arena for multidisciplinary interactions between basic and clinical scientists interested in establishing high quality translational research programs in the area of pediatric pharmacology. The Centers also will serve as national resource for the training and career development of new scientists electing to pursue careers in the conduct of translational research in high priority areas of pediatric developmental pharmacology. We (Lipshultz, Miller, Wilkinson) will likely submit a pilot study as part of this as well at \$50K/yr x 2 yr. (submission 3/22/11)

- | | | |
|-----|---|--|
| 22. | NIH (NHLBI) RO1 (Szczesna-Cordary D, PI [Univ Miami]; Lipshultz S, Consultant]: Myosin ELC, a novel therapeutic target for FHC (familial hypertrophic cardiomyopathy).
This is a competing renewal. 8/11-was scored in the fundable range. | 11/1/11-10/31/16 |
| 23. | NIH (NINDS) (Sacco R, Benatar M, Co-PIs [Univ Miami]; Lipshultz S, Investigator): Network of Excellence in Neuroscience Clinical Trials Consortium (NEXT). | Submitted 3/9/11 |
| 24. | Anna and John J. Sie Foundation University of Miami Comprehensive Center for Trisomy 21 Care and Research (Lipshultz SE, PI) | 7/1/11-6/30/16
\$2,000,000 direct/yr
Submitted 1/12/11 |
| 25. | NIH Center for AIDS Research (CFAR) (Pawha S, PI, Lipshultz SE-member of Internal Advisory Committee) | 4/1/12-3/31/17
5% effort |
| 26. | NIH-CDC. U-18 Research Demonstration Cooperative Agreements Childhood Obesity Research Demonstration. RFA-DP-11-007. (Hollar D-PI, Lipshultz SE-investigator). "P3C3: Primary Care and Public Health Approachs to Obesity Prevention for Children." Submitted 4/7/11 (Application ID: AN:3386435, Grants.gov tracking: Grant 10847355). | 11/1/11-10/31/16
~\$16,000,000 |
| 27. | Children's Cardiomyopathy Foundation (Lipshultz SE-PI) Pediatric Cardiomyopathy Research
Funded. | 7/1/11-6/30/13
\$250,000 |
| 28. | NIDA (R21 DA031976) Bandstra ES-PI
Sex differences in vascular health consequences of prenatal cocaine exposure. (Lipshultz SE – Investigator) – Not funded but in revision. | 7/1/11-6/30/13 |
| 29. | Children's Cardiomyopathy Foundation (Hare J-PI, Trachtenberg B, Lipshultz S-investigator). A molecular signature for the accurate diagnosis of myocarditis. | 1/1/12-12/31/13 |

UNIVERSITY OF MIAMI HUMAN SUBJECTS RESEARCH OFFICE PROTOCOLS – PENDING, APPROVED, AND ACTIVE PROTOCOLS WHERE DR. LIPSHULTZ IS LISTED AS INVESTIGATOR (updated 10/26/09)-26 active protocols:

MEMBERSHIP IN PROFESSIONAL SOCIETIES:

1986-current	Fellow, American Academy of Pediatrics (FAAP) (#142298)
1986-1993	Associate, American College of Cardiology

1992-2008 Premium Professional Silver Heart Member, Council of Cardiovascular Diseases of the Young, American Heart Association (#100001433053)

1994-2000 Associate Member, Pediatric Oncology Group

1996-current Member, Society for Pediatric Research

1999-current Member, American Pediatric Society

2000-2008 Premium Professional Silver Heart Member, Council on Nutrition, Physical Activity, and Metabolism, American Heart Association

2000-current Member, Children's Oncology Group

2001-2003 Member, Council on Heart Failure, International Society for Heart and Lung Transplantation

2001-2003 Member, Council on Pediatric Heart Transplantation, International Society for Heart and Lung Transplantation

2003-current Member, Association of Medical School Pediatric Department Chairs, Inc.

2003-current Member, Greater Miami Pediatric Society

2003-current Member, Florida Association of Children's Hospitals

2005-current Member, National Association of Children's Hospitals and Related Institutions (NACHRI).

2005-current Member, National Association of Children's Hospitals (NASH)

2005-2008 Premium Professional Silver Heart Member, Council of Epidemiology and Prevention, American Heart Association

2007-current Active Member, Association of American Physicians – A prestigious organization for the advancement of scientific and practical medicine. The award said “Dr. Lipshultz is an international authority in the area of pediatric cardiomyopathy and has made and continues to make seminal scientific discoveries and contributions over the past 20 years that have resulted in better outcomes for thousands of children worldwide. This includes Dr. Lipshultz's groundbreaking work in identifying cardiac late effects of chemotherapy treatment in long-term survivors of childhood cancer.”

2008-current Premium Professional Plus Gold Heart Member, American Heart Association and American Stroke Association. Membership # 156813697, Membership #100001433053 (this is the current number), Expires 06/30/2012, Fellow – Council on Cardiovascular Disease in the Young, Member – Council on Epidemiology & Prevention, Regional Affiliate: Greater Southeast Affiliate.

2009-current Fellow of the American Heart Association, Cardiovascular Diseases in the Young Council.

JOURNAL AND GRANT EDITOR OR REVIEWER:

Associate Editor (Dr. Lipshultz is currently an Associate Editor or Editorial Board Member at 14 Journals)

2007-current (#1) Progress in Pediatric Cardiology (Elsevier)

Editorial Board Member:

2003-2006 Journal of Clinical Oncology

2003-current (#2) Cardiovascular Toxicology

2003-2006 Drug Design Reviews-Online

2004-current (#3) Contributing Editor, The Cochrane Childhood Cancer Group (CCG)

2005-2007 Progress in Pediatric Cardiology (Editorial Advisory Board)

2006-2007 Pediatric Hematology and Oncology

2007-current (#4) Virology: Research and Treatment (Editorial Board)

2008-current (#5) Transplants, Research and Risk Management (Honorary Editorial Board)
 2008-current (#6) International Journal of Pediatrics (Editorial Board)-Editor for 12 manuscripts/2010
 2008-current (#7) Lymphoma and Chronic Lymphocytic Leukemias (Honorary Editorial Board)
 2008-2009 Inaugural Panelist - 2009 ASCO Educational Book Expert Panel Member.
 Repeated for 2009-2010 and 2010-2011 Books.
 2009-current (#8) Editorial Board Member. Scientific Medicine.
 2009-current (#9) Editorial Board Member. HIV/AIDS – Research and Palliative Care.
 2009-current (#10) Founding Editorial Board Member. Clinical Audit.
 2009-current (#11) Honorary Editorial Board Member. Adolescent Health, Medicine and Therapeutics. Dove Medical Press. On March 31, 2010 Dr. Lipshultz was asked to consider becoming the Editor-in-Chief of this journal from Merrill Cliffe, Commissioning Editor, Dove Medical Press.
 2009-current (#12) Invited Honorary Editorial Board Member. Patient Related Outcome Measures.
 2010-2014 (#13) Editorial Board Member, World Journal of Clinical Oncology (WJCO).
 2010-current (#14) Editorial Board Member, Journal of Postgenomics: Drug & Biomarker Development – Open Access.

Guest Editor:

1998 Progress in Pediatric Cardiology
 2000 Progress in Pediatric Cardiology
 2006 Progress in Pediatric Cardiology
 2007 Progress in Pediatric Cardiology
 2008 Progress in Pediatric Cardiology
 2010/11 Progress in Pediatric Cardiology (four issues)
 2003-2004 Circulation
 2005 Seminars in Oncology

Reviewer:

1990-current American Journal of Cardiology
 1990-current Journal of Pediatrics
 1991-current Medical Letter
 1991 Journal of Cardiovascular Nursing
 1991-current Pediatrics
 1991-current Circulation Research
 1992-current New England Journal of Medicine
 1992-current Journal of Clinical Oncology
 1992-current Bone Marrow Transplantation
 1993-current Cancer
 1993-current Journal of the American College of Cardiology
 1994-current Archives of Pediatrics and Adolescent Medicine
 1995-current American Journal of Physiology
 1995-current International Journal of Cancer
 1995-current Chest
 1996-current Clinical Chemistry
 1996-current Dutch Cancer Society
 1997-current Journal of Noninvasive Electrocardiography
 1997-current Circulation

1998-current	Southern Medical Journal
1998	Great Britain National Health Service
1998-current	Medical and Pediatric Oncology
1999-current	Journal of Pediatric Hematology and Oncology
1998-current	National Heart, Lung, and Blood Institute, NIH
1999-current	Nature Medicine
1999	Biology of Blood and Marrow Transplantation
1998-current	Food and Drug Administration
2000-current	Acta Haematologica
2000	Journal of Psychosomatic Research
2001-current	Pediatric Research
2001	Trends in Cardiovascular Medicine
2001-current	Pediatric Cardiology
2001	Nuclear Medicine Communications
2002-current	Journal of the Acquired Immune Deficiency Syndromes
2001-current	The Lancet
2001	Experimental Biology and Medicine
2002-current	Journal of Infectious Diseases
2002-current	Archives of Diseases of Childhood
2003-current	Pediatric Blood and Cancer
2004	National Medical Research Council (Singapore)
2004-current	Drug Design Reviews-Online
2004-current	Cardiovascular Toxicology
2004-current	Journal of Applied Physiology
2004-current	The Cochrane Library – Cochrane Heart Group
2004-current	American Heart Journal
2004-current	Journal of AIDS (JAIDS)
2005	Annals of Oncology
2005	Adis Drugs Evaluation
2005	Personalized Medicine
2005-current	Journal of Pediatric Hematology and Oncology
2005	Environmental Mutagenesis
2005	The American Journal of The Medical Sciences
2005-current	Cancer Chemotherapy and Pharmacology
2005	Haematologica Journal
2006-current	Biochemical Pharmacology
2006-current	CMAJ (Canadian Medical Association Journal)
2006	Clinical Advances in Hematology and Oncology
2006-current	Expert Review of Molecular Diagnostics
2006-current	Journal of the National Cancer Institute
2006	BMC Cardiovascular Disorders
2006-current	Children's Cancer Research Fund Grant Program
2006-current	Current Pharmaceutical Design
2006	Indian Journal of Medical Research
2006-current	Congenital Heart Disease
2006	Environmental and Molecular Mutagenesis
2007	Cancer Treatment Reviews

2007	Association Francaise contre les Myopathies
2007	Expert Opinion on Investigational Drugs
2007	Expert Opinion of Drug Evaluation
2007-current	Expert Review of Cardiovascular Therapy
2007	Transplantation
2007	World Journal of Pediatrics (Hangzhou, China)
2007	Journal of Viral Entry
2007	Slovak Research and Development Agency
2007	Coronary Artery Disease
2007	Anti-Cancer Drugs
2007	Annals of Internal Medicine
2007	The FASEB Journal
2007-current	Journal of The American Medical Association
2007	Journal of Neonatal-Perinatal Medicine
2007	Consultant
2007	BMC Cancer
2007	European Journal of Echocardiography
2008	Chemical Research in Toxicology
2008	Drug Safety
2008-current	Acta Paediatrica (Stockholm, Sweden)
2008	Annals of Clinical Biochemistry
2008	Psycho-Oncology
2008	Center for Integrated Research of Universita Campus Bio-Medico, Rome, Italy
2008	AIDS Research and Human Retroviruses
2008	Pediatrics International
2008	Future Cardiology
2008	Paediatrics & Child Health, the journal of the Canadian Pediatrics Society
2008	Leukemia and Lymphoma
2008-2009	ASCO Education Book
2008	International Journal of Radiation Biology
2008-current	International Journal of Pediatrics
2008	Current Medical Chemistry
2008-current	American Journal of Epidemiology
2009	Antiviral Therapy
2009	Current HIV Therapy (Bentham)
2009	Current Pharmaceutical Design (Bentham)
2009	Thrasher Research Fund
2009	Chemotherapy
2009-current	Clinical Cancer Research
2009	Annals of Clinical Biochemistry
2010	ASCO Education Book
2010	Haematologica
2010	Nature Reviews Cardiology
2010	Expert Reviews of Hematology
2010	Hypertension
2010	Cardiology Research
2010	Current Pharmaceutical Biotechnology

2011	Expert Opinion on Drug Metabolism and Toxicology
2011	Pediatric Hematology and Oncology
2011	Basic and Clinical Pharmacology and Toxicology
2011	Journal of Metabolomics and Systems Biology
2011	French National Cancer Institute, International Committee for the Clinical Research in Cancer (CIR2C), Hospital Clinical Research Programme (PHRC)
2011	International Journal of Nanomedicine
2011	Open Access Medical Statistics
2011	CA: A Cancer Journal for Clinicians
2011	Swiss Medical Weekly
2011	European Heart Journal
2011	The Netherlands Organisation for Health Research and Development (ZonMw)
2011	Coronary Artery Disease
2011	Journal of the American Society of Echocardiography

MAJOR CURRENT RESEARCH INTERESTS:

1. To prevent cardiomyopathy and heart failure in children and young adults.
2. The development of surrogate outcome measures and biomarkers of adult-onset disease, such as coronary artery disease and heart failure, helps to identify prenatal and postnatal factors that moderate their natural history. We believe that the identification, development, and validation of biomarkers of diagnosis, prognosis, efficacy and magnitude of treatment effect, toxicity, and disease activity, and intermediate surrogate endpoints of disease severity may reflect underlying pathogenesis and may substitute for clinical endpoints in clinical trials.
3. Translating research advances to clinical care through clinical trials. We have established integrated networks and infrastructure for cardiac therapeutic clinical trials and have conducted multicenter, randomized trials to test and assess new therapies for pediatric cardiovascular disease to accelerate the translation of research advances into clinical care.
4. Researching the efficacy, long-term side effects, and outcomes of pharmacological agents in children by use of cross-sectional and longitudinal approaches.
5. Preventing adult cardiomyopathic disease that originates prenatally or in childhood.
6. We have used animal models to understand clinically relevant conditions such as anthracycline cardiotoxicity to increase understanding of the formation and pathophysiology of, as well as the prevention of, cardiomyopathy.
7. One of our research objectives has been the reduction of health disparities among racial, ethnic, and social minority populations and gender by understanding the biological, gender and ethnicity, socioeconomic status, environmental, and psychological risk factors which contribute to the pathophysiology of cardiomyopathy in childhood and account for health disparities among different groups.
8. We have used comparative genomics and proteomics to study the development of pediatric cardiomyopathy. The influence of genomic variation, genotype-phenotype correlations, modifier genes, and gene-environment interactions on the development and progression of pediatric cardiomyopathy, and on therapeutic success and the incidence of adverse clinical events are actively under investigation.
9. Development of effective strategies for reducing risk factors in families and through home- and hospital-based cardiac rehabilitation programs funded by the NCI P³S² study.

10. Clinical effectiveness – We have been conducting clinical research on determinants of outcome across the many rare and diverse cardiac lesions in childhood. Research on clinical outcomes is critical to implementation and development of standards of care for pediatric cardiology.
11. Measuring general health status – We have NHLBI funding to develop, validate, and prospectively test instruments for assessing the functional status and quality of life of children with cardiomyopathy.
12. Work force for academic pediatric cardiology – We have had an NHLBI training grant to continue to develop successive generations of scientists to study pediatric cardiovascular disease.

SPONSORED RESEARCH TRAINING (INCOMPLETE – RESTRICTED TO THOSE WHO HAVE PUBLISHED WITH OR RECEIVED TRAINING GRANTS SPONSORED BY DR. LIPSHULTZ):

1. Congenital Heart Disease in the Offspring of Cocaine-Abusing Mothers - with Joseph Frassica, M.D., Began as Resident in Pediatrics, Boston City Hospital and continued as a Fellow in Pediatric Critical Care at Massachusetts General Hospital. Currently Associate Chair of Pediatrics, University of Miami Miller School of Medicine, Chief Medical Officer, Holtz Children's Hospital, Chief Medical Information Office Jackson Memorial Medical Center, Miami. Formerly was Chief of Pediatric Critical Care, Vice Chair of Inpatient Pediatrics, University of Massachusetts Medical Center, Worcester, MA. Currently NIH funded through MIT, Cambridge MA for research on information technology. Platform presentation to the American Academy of Pediatrics Annual Meeting - 1990. Two papers published in J. Pediatrics and Arch Pediatr Adolesc Med.
2. Nutritional Aspects of HIV Cardiac Disease - with Tracie Miller, M.D., Began as Fellow in Gastroenterology, Boston Children's Hospital. Former Chief of Pediatric Gastroenterology and Nutrition, University of Rochester with multiple NIH grants and with continuing research collaboration. Currently Division Director and Professor of Pediatrics, Division of Pediatric Clinical Research, Associate Chair for Clinical Research, University of Miami Miller School of Medicine. Paper in Am J Clin Nutr, 4 abstract published - 1990-2.
3. Infectious Disease and Cardiopulmonary Aspects of HIV Pediatric Disease - with Lynn Luginbuhl, M.D., Began as Fellow in Infectious Diseases, Boston Children's Hospital. Currently Attending in Pediatric Infectious Diseases, Massachusetts General Hospital, Boston, MA. Currently enrolled in Masters in Clinical Evaluation Sciences at Dartmouth Medical School. 4 Platform Presentations - 1991-2. One paper published in JAMA.
4. Clinical Predictors of Cardiovascular Morbidity and Mortality in Pediatric HIV Infection - with Inas Al-Atar, M.D., Fellow in Infectious Diseases, Boston Children's Hospital. Dr. Lipshultz was her sponsor for NHLBI-funded fellowship support. Currently Chief of Pediatrics, Princeton Hospital, Princeton, West Virginia. 2 abstracts presented 1995. 1 paper published in the Journal of the American College of Cardiology (2003) and one book chapter published.
5. Pediatric Cardiomyopathies - with Marcy Schwartz, M.D., Fellow in Cardiology, Boston Children's Hospital. Dr. Lipshultz was her sponsor for NHLBI-funded fellowship support. Currently Assistant in Cardiology, Boston Children's Hospital and Assistant Professor of Pediatrics, Harvard Medical School. Three abstracts presented (1994, 1997), 4 papers published in Circulation (1996) and American Heart Journal (2000 and 2002), and Pediatrics (2005).
6. Fetal Echocardiography in HIV+ Women - with Lisa Hornberger, M.D., Fellow in Cardiology, Boston Children's Hospital. Dr. Lipshultz was her sponsor for NHLBI-funded fellowship support. Former Pediatric Echocardiography Attending, Hospital for Sick Children, Toronto with multiple research grants. Currently Director of the Fetal Cardiovascular Program and Professor of Clinical Pediatrics, University of California, San Francisco. Abstract presented (1995), papers published in

- American Heart Journal (2000) and Progress in Pediatric Cardiology (1998). As of 2006 Dr. Hornberger published 87 papers, is editor of the leading text in her field, and has received 20 peer-reviewed research grants.
7. Cardiac Troponin-T as a Marker of Myocardial Damage in Children With Doxorubicin Cardiotoxicity - with Michael E. Ottlinger, Ph.D., DABT, Fellow in Laboratory Medicine, Boston Children's Hospital. Previously Section Chief, Clinical Pharmacology and Toxicology, Centers for Disease Control and Prevention. Currently Section Chief, National Decontamination Team, Office of Emergency Management, United States Environmental Protection Agency, Cincinnati, Ohio. Abstracts presented (1995, 1997), 2 papers in Circulation (1997) and Progress in Pediatric Cardiology (1998).
 8. Is There a Safe Cumulative Anthracycline Dose That is Not Associated With Late Cardiotoxicity in Long-Term Survivors of Childhood Cancer - a Combined Danish-US Study - with Karsten Nysom, M.D., Fellow, University Hospital, Copenhagen, Denmark. Danish Cancer Society Research Grant awarded to support Dr. Nysom's research time in my laboratory. Currently Pediatric Hematology and Oncology Attending Physician, Rigshospitalet (University Hospital), Copenhagen. Abstract presented (1997), Papers in Journal of Clinical Oncology (1998) and Progress in Pediatric Cardiology (1998). As of 2006 Dr. Nysom published 26 papers on PubMed.
 9. The Course and Prognosis in Children With Idiopathic Dilated Cardiomyopathy - The Lack of a Difference Between a Developing Nation and Developed Nations – with R. Krishna Kumar, M.D., Fellow in Cardiology, Boston Children's Hospital. Currently Chief Pediatric Cardiologist, Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala, India. One abstract presented (1996) and a manuscript accepted with revision at the International Journal of Cardiology.
 10. Cardiovascular Manifestations of HIV Infection - with Vernat J. Exil, M.D., Began as Resident in Pediatrics, Boston City Hospital. Currently an Assistant Professor of Pediatrics, Vanderbilt University School of Medicine and staff pediatric cardiologist with multiple federal research grants. While working under the supervision of Dr. Arnold Strauss, Dr. Exil was awarded a Robert Wood Johnson Minority Medical Faculty Development Award (1997-2003) to study Human defects and mouse models of cardiomyopathy, a Vanderbilt Physician Scientist Development Award (2001-2003), and an American Heart Association Southeast Affiliate Grant-in-Aid to study the role of HERS in the genesis of ventricular arrhythmias in mice in part based on this work. Dr. Exil also received the Society for Pediatric Research Young Investigator Award (1999), the Award from the Weinstein Cardiovascular Development, Council on Basic Science and the Council on Cardiovascular Disease in the Young of the American Heart Association Award (1999), a Scholar Award of the Child Health Research Center of Excellence in Developmental Biology at Washington University in Saint Louis (2000), the Outstanding Research Award in Pediatric Cardiology from the Council on Cardiovascular Disease in the Young, American Heart Association 73rd Scientific Session (2000), and the Richard D. Rowe Award in Perinatal Cardiology in recognition of research in academic pediatrics from the Pediatric Academic Societies (2002) and he dedicated this to Dr. Lipshultz. Three abstracts presented (1995 and 1997). One paper in the American Heart Journal (2003), one paper in the Journal of the American College of Cardiology (2003), one paper in the Journal of the American College of Cardiology (2004), and one book chapter published (1998).
 11. Epidemiological Studies of Cardiovascular Manifestations of HIV Infection - with Elizabeth Bancroft, M.D., S.M. Began as Graduate Student in Clinical Epidemiology, Harvard School of Public Health and continued as a Luce Scholar. Currently a Senior Epidemiologist at the Centers for Disease Control and Epidemiology. Two book chapters published (1998 and 1999).

12. Predictors of Cardiovascular Abnormalities in HIV-Infected Children - with Debra Tucker, Third Year Medical Student, Boston University School of Medicine. Received Pediatric AIDS Foundation Student Research Scholarship Award sponsored by Dr. Lipshultz to conduct this research. Manuscript in review.
13. Abnormal Neural Crest Development Results in Congenital Cardiovascular Malformations in Children with Neuroblastoma - with Karen Swanson, S.M. Began while graduate student in Clinical Epidemiology, Harvard School of Public Health. Currently Senior Epidemiologist with the California State Department of Health. One abstract published and presented (1995) and manuscript in revision.
14. Endoscopic Abnormalities in Children with HIV Infection - with Linda McQuinn, S.M., began as a graduate student in Clinical Epidemiology, Harvard School of Public Health. Received Pediatric AIDS Foundation Student Research Scholarship Award sponsored by Dr. Lipshultz to conduct this research. Currently Senior Epidemiologist with the State of Maine. Paper published in the Journal of Pediatrics (1997).
15. Infectious Correlates of Cardiovascular Disease in Children with HIV Infection - with Judith Epstein, M.D., Fellow in Infectious Diseases, Boston Children's Hospital. One article published and one book chapter published.
16. Markers of Myocardial Damage in Children with Viral Syndromes - with Julia Wong, M.D., Fellow in Pediatric Cardiology, Boston Children's Hospital. Became Chief of Pediatric Cardiology at the National University Hospital in Singapore, and is currently completing her doctorate in Clinical Epidemiology at the Harvard School of Public Health. One abstract presented (1997), one paper published in the American Heart Journal (2005), one book chapter published (1998), and one grant-supported prospective clinical trial active.
17. Comparison of Evaluation and Management of Suspected Cardiac Disease in Children by Pediatricians and Pediatric Cardiologists - with Jacques Benun, M.D., Pediatric Chief Resident, Boston City Hospital. Currently Attending Pediatrician and Associate Director of the Pediatric Residency, Brown University School of Medicine and Hasbro Children's Hospital. Recipient of numerous teaching awards. One abstract presented (1997) and one paper published in the American Heart Journal (2002).
18. A Prospective Study of Cardiac Complications in Long-Term Survivors of Childhood Hodgkin's Disease Treated With Mediastinal Irradiation - with Nandini Moorthy, M.D., NIH-funded Research Fellow in Dr. Lipshultz' group at Boston Children's Hospital. Was Pediatric Rheumatology Fellow, New York Hospital and Weill Cornell Medical College funded by an NIH T32 training grant in clinical research. Currently Assistant Professor of Pediatrics, Director, Bristol-Myers Squibb Pediatric Rheumatology Center, Department of Pediatrics and Chief, Pediatric Rheumatology Services at Robert Wood Johnson University Hospital-Bristol Myers Squibb Children's Hospital. Children's Health Institute of NJ, UMDNJ-RWJMS, New Brunswick, NJ. PI on several grants. One book chapter published (1998). Awarded First Prize Award in University of North Carolina Resident Research Competition based on this work.
19. Nutritional-Cardiac Interactions in Pediatric HIV Infection - with Michelle Hoffman, University of Rochester undergraduate student in Take 5 program. Strong Children's Research Center Summer Student Awardee to complete this project with Dr. Lipshultz as sponsor. Subsequently attended the University of Chicago Pritzker School of Medicine and is currently the Pediatric Chief Resident at the University of Nebraska Medical Center, Omaha, Nebraska. Poster presented (1997) and one book chapter published (1999).
20. Physician Compliance in Clinical Studies of Pediatric Cardiomyopathy - with Tracy Thorpe, University of Rochester School of Medicine second year student. NHLBI Summer Student

- Scholarship for Underrepresented Minority Students Awardee to complete this project with Dr. Lipshultz as sponsor. Poster presented (1997) and one review article in preparation (1997).
21. Recent Advances in Pediatric Cardiomyopathy - With Jonathan Gable, Dartmouth College undergraduate student. In 2010 was an orthopedic resident at the University of Rochester. Strong Children's Research Center Summer Student Fellowship with Dr. Lipshultz as sponsor, poster presented (1997) and one review article in preparation (1997). In 2009 was completing an Orthopedic residency at the University of Rochester.
 22. Late Cardiac Effects in Pediatric Oncology Patients and HIV-Associated Cardiovascular Problems - Amy Lee Giantris, Worked with Dr. Lipshultz as an NIH-funded research associate at Harvard and the University of Rochester for three years. Became University of Vermont School of Medicine medical student (MD-2001). Completed a pediatrics residency at Yale (2001-4). In 2007 Dr. Giantris was an Assistant Professor of Pediatrics at the University of Texas. Three book chapters published (1998 and 1999), two articles published (1998, 2002).
 23. HIV-Associated Heart Disease - with Anne-Marie Boller, MA, Worked with Dr. Lipshultz as an NIH-funded research assistant for two years while obtaining her MA in Medical Sciences at Boston University School of Medicine. Subsequently became a University of Minnesota School of Medicine medical student (MD-2000), general surgical resident at Hennepin Co Med Ctr, two one year fellowships in colon and rectal surgery at the Mayo Clinic in Rochester, a third year fellowship at the Univ of Minn Pelvic Floor Center, and in 2008 is a full-time Assistant Professor of Surgery specializing in Colorectal Surgery in the Division of Gastrointestinal and Oncologic Surgery in the Department of Surgery at Northwestern University, Chicago. Dr. Boller directs the anorectal physiology efforts at Northeastern University, is part of the Colon and Rectal Surgery Training Program, and is heavily involved in the Women's Pelvic Health Center that opened in 2009. Dr. Boller's research interests include laparoscopic rectal cancer surgery, hereditary colon cancer, sacral nerve stimulation and functional and quality of life outcomes following pelvic floor surgery. While with Dr. Lipshultz Dr. Boller published three book chapters (1998 and 1999).
 24. Cardiac Complications in Long-Term Survivors of Childhood Cancer - with Suzanne M. Mone M.S., M.D. Worked as a pediatric cardiology technician with Dr. Lipshultz from 1984 to 1993. Then as a medical student at St Georges's University School of Medicine, Newark New Jersey, and then as a Pediatric Resident, University of Rochester Pediatric Residency Program. Became Pediatric Cardiology Fellow, Children Hospital Medical Center, Cincinnati, OH and then an Interventional Pediatric Cardiology Fellow at Stanford University. Six papers published, 8 abstracts presented. In 2008 Dr. Mone was a board certified pediatric cardiologist at Morristown Memorial Hospital in Morristown, New Jersey
 25. Radiation-Associated Heart Disease - with Elizabeth H. Cameron, M.D., Radiation Oncology Fellow, Harvard Joint Center for Radiation Therapy, and MPH candidate, Harvard School of Public Health. One paper published (1998), one presentation given, one paper in preparation.
 26. Growth Hormone Therapy-Associated Cardiac Effects in Survivors of Childhood Cancer - with Sarah Vlach, Became Mayo Medical School third year student. Recipient of Mayo Medical School Student Research Award, American Heart Association Student Research Fellowship Award, Clausen Student Research Fellowship Award, and James A. Manning Pediatric Cardiology Research Award to work on this study. Abstract presented, one paper published in the Journal of the American College of Cardiology, another paper published in Pediatrics (2005). In 2008 Dr. Vlach was a specialist in Physical Medicine and Rehabilitation and in Pediatric and Adolescent Psychiatry at Willamette Valley Medical Center in Oregon.
 27. Radiation Heart Disease - (Michael) Jacob Adams, M.D., M.P.H., Began research with Dr. Lipshultz as a Pediatrics Resident, Children's Hospital at Strong in 1998. Recipient of Gilbert

- Forbes Housestaff Research Award, the James A. Manning Fellowship in Pediatric Cardiology from 9/1998 to 7/1999, Gilbert Forbes Fellowship for House Officer Research, Department of Pediatrics, University of Rochester 1998-9, the University of Rochester Cancer Center's John Wilmott and Jane A. Mason Memorial Endowment Summer Research Fellowship in Cancer Research with Dr. Lipshultz between 9/1998-7/1999. Research Associate in Pediatric Cardiology at University of Rochester with Dr. Lipshultz from 1999-2000. From 8/2000-7/2003 was a Research Fellow in the Division of Pediatric Cardiology with Dr. Lipshultz studying Cardiac Risk Factors in Long-Term Survivors of Childhood Cancer. From 8/2000 to 7/2002 Dr. Adams was a NHLBI Preventive Cardiology Training Grant awardee under Dr. Lipshultz' partial supervision (Post Doctoral Fellow in NHLBI Funded Preventive Cardiology Training Program [2T32HL07937]). From 2002-2005 was funded as a Wilmot Cancer Research Fellow at the University of Rochester for work with Dr. Lipshultz. Currently a recipient of an NHLBI K23 Mentored Patient Oriented Research Career Development Award on Cardiovascular risk 50 years after thymic irradiation with Dr. Lipshultz as co-mentor to continue to study late cardiovascular effects of mediastinal irradiation. Currently an Assistant Professor, Division of Epidemiology, Department of Community and Preventive Medicine, University of Rochester School of Medicine. Past recipient of James P. Wilmot Cancer Epidemiology Research Fellowship grant. President of the Candlelighters Childhood Cancer Foundation. Author on two papers, first author on ten review articles/chapters (1998-2006), and seven abstracts from 1999-2006. Also actively involved in completing a large prospective study.
28. HIV Heart Disease - Stacy D. Fisher, M.D., was Chief Fellow in Adult Cardiology and the Attending in Adult Cardiology and Fellow in Pediatric Cardiology (Adult Congenital Heart Disease), University of Rochester Medical Center. Supported by Dr. Lipshultz' NIH funding. Author on six chapters, 4 papers, 10 review articles, and working on projects currently. Currently a Partner and Staff Cardiologist at Midatlantic Cardiovascular Associates in Baltimore MD and Director of Cardiology Education at Sinai Hospital in Baltimore where she has won several teaching awards including the Sinai Hospital Golden Apple Teaching Award four years in a row. Dr. Fisher is also the Director of Women's Cardiovascular Services at Sinai Hospital, and is the Co-Director of Sinai's Cardiac Critical Care Unit. In October 2008 Dr. Fisher was recognized by Baltimore Magazine as one of the seven top doctors in Baltimore.
 29. Adolescent Hypertension – Mark Fox, M.D., Ph.D., Medicine-Pediatric Resident, University of Rochester School of Medicine. Recipient of the American Academy of Pediatrics Housestaff Research Award and University of Rochester Department of Pediatrics Housestaff Research Award. On NHLBI Preventive Cardiology training grant. Recipient of K23 award and faculty position at the University of Oklahoma School of Medicine. Working on projects currently. (2001).
 30. HIV Cardiac Disease in Children - Marcie J. Keesler, NIH-supported research study coordinator with Dr. Lipshultz and student in the University of Rochester MPH program in clinical epidemiology. First author on one peer-reviewed article (2001) and on one chapter (2001).
 31. Anthracycline Cardiotoxicity and Neonatal Cardiac Injury Assessed by Serum Cardiac Troponin T – Valeriano Simbre II, MD, Pediatric Cardiology Fellow, University of Rochester School of Medicine. Continued on to do an Interventional Pediatric Cardiology Fellowship at Stanford. First author on one peer-reviewed article (2001) and author on 4 other articles (2001-8). First author on abstract accepted to PAS (2002) and one to the ACC (2003). Pediatric Grand Rounds presentation of fellow research (2002).

32. Kawasaki Syndrome, Congestive Heart Failure in Pediatrics Medications, and HIV Heart Disease - William Harmon, MD, Assistant Professor of Pediatrics (Pediatric Critical Care and Cardiology), University of Rochester School of Medicine. Former Pediatric Cardiology Fellow, University of Rochester School of Medicine. In September 2008 will become Director of Pediatric Cardiac Critical Care and Associate Clinical Professor of Pediatrics at the University of Miami Miller School of Medicine. First author on one review article and two peer reviewed articles (2001, 2002). Actively working on NHLBI Pediatric Cardiomyopathy Registry as head of writing group investigating use of medications in pediatric ventricular dysfunction (one platform presentation and one poster presentation - 2004).
33. Anthracycline Cardiotoxicity - Sampeda Deshpande, Graduate Student in Clinical Epidemiology, University of Rochester School of Medicine. Subsequently received MPH from Emory University School of Public Health. Supported by Dr. Lipshultz' NIH funding. Author on 2 publications (2001, 2002).
34. Anthracycline Cardiotoxicity - Sarah Duffy, Graduate Student in Clinical Epidemiology, University of Rochester School of Medicine. Supported by Dr. Lipshultz' NIH funding. Author on 4 publications (2001-2005).
35. Serum Cardiac Troponin T in Ill Children - Karolina Zareba, MD - Undergraduate Student, University of Rochester. Currently Medicine Resident, Northwestern, Chicago. Graduated from the University of Rochester School of Medicine and Dentistry. Supported by Dr. Lipshultz' NIH funding. First author on three articles and author on four others (2001-2005).
36. Neonatal Myocardial Injury - Tina Lipinczyk, Graduate Student in Clinical Epidemiology, University of Rochester School of Medicine. Supported by Dr. Lipshultz' NIH funding. Author on abstract accepted at PAS (2002) and first author on paper published in the Journal of Clinical Oncology Review (2005).
37. Late Effects of Therapy for Childhood Cancer - Brenda Wittman, MD, Pediatric Hematology-Oncology Fellow, University of Rochester Medical Center. Supported by NIH training grant (T32). Research Mentor – Dr. Lipshultz. (2002).
38. HIV Heart Disease, Outcomes of a Virtual Regionalized Pediatric Cardiac Surgical Program, and Use of Electron Beam CT Scans in Kawasaki Disease Survivors – Gul H. Dadlani, MD, Second year Pediatric Cardiology Fellow, University of Rochester Medical Center. First author on 2 papers (2005), 2 chapters (2002), author on several other publications. Presented at AHA annual sessions with press release (2001) and at ACC annual sessions (2003).
39. Cardiotoxicity of Cancer Chemotherapy – Karlijn Wolters, MD. Fourth year medical student. University of Amsterdam, The Netherlands. Received training grant from the Dutch Cancer Society to do a fellowship with Dr. Lipshultz. First author on paper in the British Journal of Haematology (2005). Two other manuscripts in development.
40. Pediatric Cardiomyopathy - Jorge Alvarez. Currently a MD-PhD student at the University of Miami School of Medicine who completed his PhD in Clinical Epidemiology in summer 2009. in part with Dr. Lipshultz. Dr. Alvarez' dissertation was titled "Baseline predictors of outcomes in pediatric dialted cardiomyopathy" using analyses of the PCMR dataset. Funded from one of Dr. Lipshultz' NIH grants. Five papers published (2005-8). One first author peer reviewed paper published and another non-first author paper in press (2007). Oral presentation of results at international meeting with abstract as a selected young investigator (2007). Recipient of scientific award for his presentation at a national meeting (2006). Dr. Alvarez received an NIH NHLBI F31 grant (HL094100-01) with Dr. Lipshultz as Sponsor that received a score of 160 and was funded. Many other publications have occurred. In February 2010 Dr. Alvarez will be presenting an

- abstract at the AHA epidemiology meeting. He is completing two manuscripts related to his dissertation.
41. Pediatric Cardiovascular Complications of HIV Infection and its Therapy. Tanvi Sharma, M.D. Started as a Fellow in Pediatric Infectious Diseases and continued as an Assistant Professor of Pediatrics, University of Miami Miller School of Medicine. Had been funded from one of Dr. Lipshultz' NIH grants. Published review article on congestive heart failure, an abstract at the PAS annual meeting in 2006. Published a first author article in 2007 and another several in progress. Became an Assistant Professor of Pediatrics at Harvard Medical School in September 2007. Received a score of 202 on the first submission of an NIH NIDDK K23 Patient Oriented Clinical Research Career Development Award with Dr. Lipshultz listed on "The Role of Mitochondrial Toxicity on Metabolic Complications of Pediatric HIV" for \$587,750 total costs over 5 years. A resubmission brought this score down to the 180s. Dr. Sharma received several other grants (Micah Batchelor Award for \$225,000 over 3 years and Green Family Health Initiative for \$15,000) and publications as well.
 42. Pediatric Metabolic Syndrome and Preventive Cardiology - Sarah Messiah, PhD, Assistant Professor of Pediatrics, University of Miami Miller School of Medicine. Funded from one of Dr. Lipshultz' NIH grants. Published review article on pediatric hypertension with Dr. Lipshultz (2006) and has 2 manuscripts on Pediatric Metabolic Syndrome from the NHANES data that have been published in the Journal of Pediatrics in 2008 with Dr. Lipshultz as a co-author. Submitted a new investigator NHLBI RO1 application 6/1/06 with Dr. Lipshultz on analyses of longitudinal echo data from his PCMR grant. Other publications and grants (received a grant from the Thrasher Foundation and another from the Health Foundation of South Florida) as well. One of only two studies chosen for international publicity by the American Heart Association Epidemiology meeting (2008). PI on second large Thrasher Foundation research grant (2008). Keynote speaker at the Consortium to Lower Obesity in Chicago Children, Children's Memorial Hospital (2008). Received a score of 151 on first submission to NIH of a K01 application that is likely to be funded with Dr. Lipshultz as a co-mentor.
 43. Associations Between Markers of Inflammatory Activation and Heart Failure in Children. Christopher Ratnasamy, M.D. – Third year pediatric cardiology fellow, University of Miami Miller School of Medicine. Became a faculty member in the same program. Has had papers published as first author in the American Heart Journal and Progress in Pediatric Cardiology in 2008 and 8 abstracts as well.
 44. Bioethical Issues in Pediatric Cardiomyopathy and Heart Transplantation. Kristin C. Sokol – Worked with Dr. Lipshultz as a second year medical student, University of Miami Miller School of Medicine. In 2010 was a Resident in Pediatrics at Texas Children's Hospital, Houston (Baylor College of Medicine). Did a full-time research year funded on NIH studies focused on pediatric cardiomyopathies as well as completing a Master's degree in bioethics. First author on book chapter and on 2 peer reviewed journal article in 2007 and 2008.
 45. Exercise Physiology in Long Term Survivors of Childhood Cancer. Angela Milton – MPH student at the University of Miami Miller School of Medicine. NIH supported study coordinator in pediatric cardiomyopathy. Beginning PhD in Epidemiology at Emory in July 2008. Several manuscripts and 2 abstracts in 2006 and 2007.
 46. Biomarkers for Cardiomyopathy in Children at Risk for Cardiomyopathy. Rebecca E. Scully – Dartmouth College graduate completing pre-medical studies at the University of Miami. NIH funded study coordinator in cancer survivorship. Accepted to Dartmouth Medical School 11/08. 12 papers, some as first author, book chapters, and abstract in 2006-2008. 2010 American Society of Hematology Predoctoral Fellowship Grant to continue research with Dr. Lipshultz.